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Abbreviations  
 
3-MC:  3-Methylcholanthrene 
Ad-CRE: Adenoviruses expressing CRE recombinase 
Ad-GFP: Adenoviruses expressing GFP 
BAC:  Bacterial Artificial Chromosomes  
BrdU:   Bromodeoxiuridine 
BSA:   Bovine Serum Albumin 
cDNA:  Commplementary DNA 
CMV:   Cytomegalovirus promoter 
CNIO:  Centro Nacional de Investigaciones Oncológicas 
DMBA: 7,12-dimethylbenz[]anthracene  
DMEM:  Dulbecco‟s Modified Eagle‟s Medium 
DMSO:  Dimethyl sulfoxide 
EDTA:  Ethylenediaminetetraacetic Acid  
ES cells:  Embryonic Stem Cells 
EV:   Empty Vector 
FBS:   Fetal Bovine Serum  
GAPDH:  Glyceraldehyde-3-phosphate dehydrogenase 
GFP:   Green Fluorescence Protein  
H&E:  Haematoxylin and Eosin 
HR:   Homologous Recombinantion 
IF:   Immunofluorescence 
IHQ:   Immunohistochemistry 
KDa:   KiloDalton 
KO:   Animals or cells derived from a gene knock-out strain  
KI:   Animals or cells derived from a gene knock-in strain  
LacZ:   beta-galactosidase 
MEFs:  Mouse Embryonic Fibroblasts 
MMTV: Mouse mammary tumour virus promoter 
NEO:   Neomicine 
PBS:   Phosphate Buffered Saline  
PCR:   Polymerase Chain Reaction 
PFA:   Paraformaldehyde 
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qRT-PCR:  quantitative Reverse Transcriptase Polymerase Chain Reaction  
rtTA:   reverse tetracycline Transactivator 
SDS:   Sodium Dodecyl Sulphate 
shRNA:  short hairpin RNA  
siRNA:  small interference RNA  
Tet:   Tetracycline 
TetO:   Tetracycline Operator elements 
Tet-P:   Tetracycline-responsive minimal promoter 
Tg:   Transgenic mice 
TK:   Thymidine Kinase  
TPA:  12-O-tetradecanoylphorbol-13-acetate  
tTA:   tetracycline Transactivator 
UAM:   Universidad Autónoma de Madrid 
UTR:   Untranslated region 
WB:  Western-Blot  
WT:   Wild Type 
X-GAL:  5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside
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Summary 
Aurora kinases are critical regulators of the cell cycle and their inhibition may have beneficial 
effects in cancer therapy. Aurora B interacts with Survivin, Borealin and Incenp to form the 
Chromosomal Passenger Complex (CPC), which is involved in the regulation of microtubule-
kinetochore attachments and cytokinesis. In this work, we have characterized a new regulatory 
mechanism of Aurora B based on posttranslational modification by SUMO peptides. SUMOylation 
of Aurora B regulates its localization at kinetochores and may also modulate its activity during 
mitosis. In addition, we have generated and characterized the first loss-of-function models for 
Aurora B function in mammals. Using these models we have observed that Aurora C, but not 
Aurora B, is required for cell division in early zygotes. Whereas genetic disruption of the CPC 
proteins (Incenp, Survivin or Borealin) results in early embryonic lethality at the morula stage, 
Aurora B-null embryos get implanted and die at post-implantation stages due to mitotic defects. 
This is due to the critical function of Aurora C during these embryonic cycles. Acute deletion of 
Aurora B in somatic cells that do not express Aurora C results in delayed G1/S progression from 
quiescence in vitro and in vivo, suggesting ubiquitous mitotic-independent functions of this kinase. 
Aurora B-null cells display chromosomal misalignment in the absence of Mad2 at the kinetochores. 
In addition, lack of Aurora B results in the formation of multiple -tubulin-positive microtubule 
organizing centers (MTOC) and aberrant astral microtubule nucleation. Thus, complete genetic 
ablation of Aurora B suggests a critical role for this protein in preventing supernumerary MTOCs 
and modulating microtubule dynamics during mitosis.  
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Resumen 
La familia de quinasas Aurora son reguladores cruciales del ciclo celular y su inhibición parece 
tener efectos terapéuticos en cáncer. Aurora B forma parte del complejo pasajero de los 
cromosomas (CPC) formado por las proteínas Survivina, Borealina e Incenp, el cual regula 
importantes funciones durante la fase de mitosis tales como las interacciones entre los microtúbulos 
y los cinetocoros y el proceso de citocinesis. En este trabajo hemos caracterizado un nuevo 
mecanismo de regulación de Aurora B basado en la modificación post-traduccional a través de los 
péptidos de SUMO.  La SUMOilación de Aurora B regula su localización en el centrómero de los 
cromosomas y parece que también es capaz de modular su actividad durante mitosis. Además, 
hemos generado y caracterizado los primeros modelos animales de pérdida de función de Aurora B 
en mamíferos. Gracias a estos modelos hemos observado que Aurora C, pero no Aurora B, es 
necesaria para la división celular en embriones tempranos. Mientras que la pérdida de función de 
las proteínas del CPC (Incenp, Survivina o Borealina) produce letalidad embrionaria en el estadio 
de mórula; los embriones que carecen de Aurora B son capaces de desarrollarse hasta implantarse 
en el útero materno momento en el cual mueren debido a defectos mitóticos. Este inesperado 
resultado es consecuencia de la función compensatoria que ejerce Aurora C durante los primeros 
ciclos embrionarios. Por otro lado, la eliminación aguda de Aurora B en células somáticas que no 
expresan Aurora C, produce un retraso en la progresión G1/S del ciclo celular, tanto in vivo como 
in vitro, en aquellas células que estaban en un estado de quiescencia anterior, lo cual sugiere que 
Aurora B tiene funciones ubicuas independientes de las ya descritas en mitosis. Además, hemos 
observado que las células que carecen de Aurora B presentan problemas a la hora de alinear los 
cromosomas durante mitosis y que estos problemas aparecen cuando el regulador Mad2 está 
ausente en los cinetocoros. Por último, la ausencia de Aurora B da lugar a la formación de 
múltiples centros organizadores de microtúbulos y produce defectos en la nucleación de los 
microtúbulos del aster. De esta manera, la eliminación genética de Aurora B sugiere que esta 
proteína es esencial para prevenir la aparición de múltiples centros organizadores de microtúbulos, 
y que además modula la dinámica de los microtúbulos durante mitosis. 
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Introduction 
1. The mammalian cell division cycle 
Ever since Rudolf Virchow (1821–1902) proclaimed his famous “Omnis Cellula e cellula” („All 
cells are derived from cells‟), the challenge has been to understand how cells divide and how they 
faithfully transmit genetic information from one cell generation to the next. A basic eukaryotic cell 
cycle consists of four phases (Figure 1). Basically, a cell replicates its genetic material during S 
phase (DNA synthesis) and segregates this material into two daughter cells during M phase 
(mitosis) with the posterior division of the cytoplasm (cytokinesis). The preparation stage for S 
phase, in which the cell grows, is called G1 (gap 1); while the period between S phase and M 
phase, in which the cell prepares for cell division, is called G2 (gap 2). In mammals, the majority of 
the adult cells are in a quiescent phase named G0, and only in the presence of specific mitogenic 
stimuli or signals cells decide to progress through the cell cycle (Figure 1). The G1, S, and G2 
phases are also known as interphase since no dramatic morphological changes are observed in these 
phases.   
 
 
 
 
 
Figure 1. Cell cycle phases. Quiescent cells are in G0. 
Cells that decide to cycle enter into G1 to prepare DNA 
synthesis that occurs in S phase. Once the genome is 
duplicated, cells prepare to divide during G2. Finally, 
chromosome segregation and cell division takes place in 
M phase. 
 
 
 
 
 
Mitosis is the process of nuclear division in which the previously duplicated genome is 
structurally reorganized into compact chromosomes, each made up of two identical sister 
chromatids that are equally segregated into two daughter cells. The result of the mitotic process is 
that each daughter cell inherits one complete set of chromosomes, apart from one centrosome (the 
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main microtubule- organizing centre of animal cells) and the appropriate complements of the 
cytoplasm and organelles. Mitosis is divided into five different phases: prophase, prometaphase, 
metaphase, anaphase and telophase (Figure 2a). During prophase, interphase chromatin condenses 
into well-defined chromosomes and previously duplicated centrosomes migrate apart, thereby 
defining the poles of the future spindle apparatus. Prometaphase abruptly starts when the nuclear 
envelope breakdown. During this stage, a highly dynamic bipolar array of microtubules called 
mitotic spindle is formed. Spindle microtubules are then captured by kinetochores (specialized 
proteinaceous structures associated with centromere DNA on mitotic chromosomes) (Figure 2b). 
Subsequently, mono-oriented chromosomes establish an interaction with microtubules from the 
opposite pole and become bi-oriented. Chromosomes then congress and reach the equator of the 
spindle forming what it is called the „metaphase plate‟. After all chromosomes have undergone a 
proper bipolar attachment, a sudden loss in sister-chromatid cohesion triggers the onset of 
anaphase. This event is called the „metapahase to anaphase transition‟. During early anaphase, 
chromosomes lose their cohesion, split apart and each chromatid moves towards one spindle pole. 
At late anaphase, the spindle elongates separating furthermore the two groups of chromatids. In 
telophase, the two sets of daughter chromosomes reach the poles of the spindle, chromatin starts to 
decondense and the nuclear envelope reforms around the daughter chromosomes.  
Cytokinesis is the process of cytoplasmatic division, and its regulation is intimately linked to 
mitotic progression. At the end of telophase, a contractile ring assembles at the cortex of the cell to 
partition the whole cytoplasm into two daughter cells. This contractile ring ultimately gives rise to 
the midbody (a dense bundle of microtubules derived from the telophase central spindle) that 
indicates the abscission site. The whole process is finished when abscission completely separates 
the cytoplasm of the two new daughter cells.    
2. Cell cycle checkpoints  
2.1 Interphase and the Restriction point 
To ensure proper progression through the cell cycle, cells have developed a series of checkpoints 
that prevent them from entering into a new phase until they have successfully completed the 
previous one (Malumbres and Barbacid, 2001). The first important decision that a quiescent cell 
has to make is whether to cycle or not. Different pathways, named as signal transduction pathways, 
monitor the environment and the size of the cell and inform the cell about the balance between the 
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mitogenic and anti-mitogenic signals. Considering this information cells will make a decision, 
which will be reversible until the restriction point is reached (Pardee, 1974). However, once this 
point is passed, around mid-G1, cells are compromised to replicate its genome and to finish 
mitosis. This is an extremely important decision since cycling under improper conditions can 
cooperate with tumor progression. Indeed, cancer cells often show alterations in the signal 
transduction pathways that lead to proliferation in response to external signals (Hanahan and 
Weinberg, 2000).  
2.2 DNA damage checkpoints 
Maintenance of a stable genome is also a critical event to prevent apoptosis, senescence and 
malignant cell transformation. When mammalian cells contain damaged DNA, a complex 
mechanism named the DNA Damage Checkpoint is able to sensor this damage and transduce the 
signal to activate the p53 and the retinoblastoma (pRb) tumor suppressor pathways. Activation of  
 
Figure 2. The phases of mitosis and a structural view of a mitotic chromosome. (a) Replicated interphase chromatin is 
condensed and kinetochores assembled during prophase. After nuclear envelope breakdown, during prometaphase, 
kinetochores interact with microtubules. By metaphase, bi-orientated chromosomes align in the middle of the bipolar 
spindle. Sister chromatids are pulled apart in anaphase and chromatin decondenses at telophase at the same time that 
the nuclear envelope is reformed. (b) Scheme of a mitotic chromosome. Kinetochores are assembled on the centromere 
regions of each sister chromatid to interact with microtubules. Microtubules are shown in green, nuclear envelope in 
grey, centrosomes in orange, chromatin in blue and kinetochores in red. (Adapted from (Cheeseman and Desai, 2008)). 
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these pathways prevents cells from entering DNA replication or mitosis when DNA is damaged, 
providing an opportunity for DNA repair (Bartek et al., 2004; Kastan and Bartek, 2004; Lukas et 
al., 2006). The DNA Damage Checkpoint can arrest cell cycle progression before, during or after S 
phase. 
2.3 The Spindle Assembly Checkpoint 
Correct chromosome segregation during cell division is essential to maintain an intact genome. 
Errors in chromosome partition can result in daughter cells that have inherited too many or too few 
chromosomes, a condition associated with cancer development that it is known as aneuploidy 
(Holland and Cleveland, 2009). To ensure high fidelity of chromosome segregation cells have 
developed a surveillance mechanism called the Spindle Assembly Checkpoint (SAC) that delays 
the onset of anaphase until all chromosomes are properly bi-orientated on the mitotic spindle 
(Figure 3). The effector of the SAC, known as the mitotic checkpoint complex (MCC), is located at 
unattached kinetochores and is composed by three proteins, Mad2, BubR1 and Bub3. The MCC 
inhibits the ability of Cdc20 to activate the ubiquitin ligase anaphase-promoting 
complex/cyclosome (APC/C). Once all the chromosomes are properly oriented on the spindle, the 
SAC is satisfied and Cdc20 is free to activate the APC/C-mediated polyubiquitylation of two key 
substrates, cyclin B and securin, thereby tagging its destruction by the proteasome. Securin is an 
inhibitor of a protease known as separase which is required to cleave the cohesin complex that 
holds sister chromatids together. Cleavage of cohesin is necessary to execute anaphase. On the 
other hand, proteolysis of Cyclin B is required to inactivate Cdk1 and this event is essential for 
exiting mitosis. 
3. Control of mitosis and cytokinesis by post-translational modifications 
The regulation of the last steps of the cell cycle relies predominantly on two post-translational 
mechanisms: protein phosphorylation and ubiquitin-mediated proteolysis. Both mechanisms are 
linked together since the proteolytic machinery is controlled by phosphorylation, and many kinases 
are downregulated by degradation. Deregulation of one of these post-translational modifications 
will affect the other resulting in uncontrolled proliferation, genomic instability and cancer.  
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Figure 3. The Spindle Assembly 
Checkpoint. The checkpoint 
effector (MCC) is located at 
unattached kinetochores inhibiting 
Cdc20 binding to the APC/C. Bi-
orientation of all the chromosomes 
provokes Cdc20 release, which 
now can activate the APC/C. This 
results in the polyubiquitination of 
anaphase substrates such as 
Cyclin B and Securin, and their 
subsequent proteolytic 
degradation, which leads to the 
activation of separase and the 
inactivation of Cdk1, respectively. 
(Adapted from (Musacchio and 
Salmon, 2007)). 
 
3.1 Ubiquitination and SUMOylation 
3.1.1 Ubiquitination  
Protein degradation mediated by ubiquitin has emerged to be a very powerful mechanism to 
regulate cell cycle progression (Nakayama and Nakayama, 2006). This mechanism consists on 
assembling polyubiquitin chains on substrates to target them for degradation by the 26S 
proteosome. Ubiquitin is covalently conjugated to a lysine residue of a target protein by an 
enzymatic cascade involving an ubiquitin-activating enzyme (or E1), an ubiquitin-conjugating 
enzyme (or E2) and an ubiquitin-ligase (or E3) (Thornton and Toczyski, 2006). The substrate 
specificity of this pathway relies on the ubiquitin ligases. The main ubiquitin ligases complexes 
are: the SCF (Skp1 / cullin / Fbox proteins) that regulates the progression through the end of G1 to 
the beginning of M phase and the APC/C (anaphase-promoting complex/cyclosome) that it is 
active from mitosis to the end of G1 (Nakayama and Nakayama, 2006). 
APC/C complex is regulated by the binding of the two cofactors, Cdc20 and Cdh1. The 
binding of these cofactors is, in turn, regulated by Cdks in that, phosphorylation of APC/C 
components is required for Cdc20 binding and impairs Cdh1 binding. Whereas Cdc20 activates 
APC/C during early mitosis, Cdh1 is responsible for APC/C activity from late mitosis till the G1/S 
transition (Peters, 2006). Both Cdc20 and Cdh1 recognize APC/C substrates by interacting with 
specific motifs such as the D-box (Fang et al., 1998), KEN-box (Pfleger and Kirschner, 2000), or 
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A-box (Littlepage and Ruderman, 2002). By recognition of these motifs, APC/C targets A-type 
cyclins (during G2/M) and B-type cyclins (metaphase-to-anaphase transition) for degradation, 
thereby controlling Cdk activity. In addition, APC/C regulates progression through mitosis by 
ubiquitinating several mitotic kinases such as Plk1, Aurora A, Aurora B and Nek2. Finally, in 
coordination with the SAC, APC/C-Cdc20 initiates anaphase by targeting the separase inhibitor, 
securin and cyclin B, for destruction (Peters, 2006). 
3.1.2 SUMOylation 
SUMOylation is a highly dynamic and reversible type of post-translational modification. Like 
ubiquitination, SUMOylation modulates protein function through post-translational covalent 
attachment of small ubiquitin-related modifiers (SUMOs) to lysine residues within targeted 
proteins (Geiss-Friedlander and Melchior, 2007). In vertebrates at least three SUMO forms 
(SUMO1, 2 and 3) are expressed. Human SUMO-1 is 45% identical to human SUMO-2 or -3, 
while SUMO-2 an-3 are 95% identical to each other and phenotypically indistinguishable. SUMO 
is covalently attached to a lysine residue, usually in the consensus modification site -Lys-X-Glu 
(where  is a hydrophobic residue and X is any amino acid), in three enzymatic steps analogous to 
the ubiquitination cascade. SUMO conjugation requires a SUMO-activating E1 enzyme 
(SAE1/SAE2), the SUMO-conjugating E2 enzyme Ubc9 and, in some cases, additional E3 SUMO-
ligases (Hay, 2005). SUMO modification is reversible by the action of SUMO-specific 
isopeptidases that belong to the family of ubiquitin-like proteases (Ulps), also known as sentrin-
specific proteases (SENPs) (Hay, 2007) (Figure 4). 
 In contrast to poly-ubiquitination that targets proteins for degradation, SUMOylation has 
been shown to play a crucial role in the regulation of the activity of numerous cellular processes, 
including nuclear transport, genome integrity, signal transduction, and transcriptional regulation 
(Hay, 2005; Ulrich, 2008). The molecular consequences of SUMOylation are target specific, and 
can positively or negatively influence interactions with proteins, DNA or other macromolecules. 
Potentially, SUMO can affect any aspect of a target protein, including stability, localization or 
activity (Geiss-Friedlander and Melchior, 2007). Recent work has revealed the importance of 
SUMOylation for mitotic progression (Dasso, 2008; Watts, 2007) and has outlined a critical role of 
SUMO in kinetochore/centromere function (Dawlaty et al., 2008; Di Bacco et al., 2006; Klein et 
al., 2009; Zhang et al., 2008b).  
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SUMO can also mediate non-covalent interactions with proteins containing SUMO 
interaction motifs (SIMs) (Song et al., 2004). An exciting role for SIMs was recently shown for a 
family of E3 ubiqutin ligases (Rnf4 in mammals and Rfp1/Hex3-Slx8 in yeast) which can 
specifically recognize SUMO-containing substrates via their SIM motif (Prudden et al., 2007; Sun 
et al., 2007; Uzunova et al., 2007). This opens up the possibility that SUMOylation can act as a 
signal for the recruitment of E3 ubiquitin ligases, which leads to the ubiquitylation and degradation 
of the modified protein (Geoffroy and Hay, 2009).  
 
Figure 4. SUMO conjugation and deconjugation. (a) SUMO cycle of conjugation and deconjugation. SUMO (Su, yellow) 
is processed by a SUMO-specific protease (SENP, red) before being activated and covalently linked to the SUMO E1-
activating enzyme (SAE1–SAE2, green). SUMO is then transferred to the SUMO E2-conjugating enzyme (Ubc9, white), 
which carries out target (blue) modification with the aid of a SUMO E3 ligase (E3, purple). Deconjugation to release free 
SUMO and target is mediated by a SENP. (b) SUMO-1 is distinct than SUMO-2 modification. Lysine acceptor residues 
subject to SUMO modification are usually found in the SUMO modification motif cKxE (where c is I, V or L). This motif is 
found in the N-terminal region of SUMO-2 and SUMO-3 but not in SUMO-1. Thus, SUMO-2 (and SUMO-3) can form 
polymeric chains through conjugation at the cKxE motif. (Adapted from (Hay, 2007)). 
3.2 Phosphorylation 
Progression through the entire cell cycle requires the controlled activation of different families of 
kinases that regulate by phosphorylation diverse cellular processes required for cell division (Fig 
5). Some of them, such as the Cyclin-Dependent Kinases (Cdks), are involved in the regulation of 
different cell cycle phases.  Indeed, the Cdks, which  are heterodimeric protein kinases composed 
of a catalytic subunit known as Cdk  and a regulatory subunit known as cyclin, regulate cell cycle 
commitment, DNA synthesis and the onset of mitosis (Malumbres and Barbacid, 2005). Cyclins‟s 
expression and degradation impose successive waves of kinase activation and inactivation 
controlling the progression of the cell cycle. Mitogenic signals are detected by the expression of D-
type cyclins that bind and activate Cdk4 and Cdk6 during G1 to prepare the cell for DNA 
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replication. Activation of the complex Cdk4/6-cyclin D partially phosphorylates and inactivates 
pRb proteins that in turn allow the expression of E-type cyclins. E-cyclins bind and activate Cdk2 
during the beginning of S phase and trigger the initiation of DNA synthesis. At the end of S phase, 
Cdk2 is then activated by cyclin-A2 to promote progression to G2. Finally, Cdk1 is activated by A-
type cyclins to facilitate entry into mitosis. After the nuclear envelope breakdown, A-type cyclins 
are degraded and Cdk1 is then activated by cyclin-B. The Cdk1/cyclin B complex, also known as 
MPF (maturation promoting factor) is considered as the „master regulator‟ of mitosis. This complex 
regulates many events at the onset of mitosis including nuclear envelope breakdown, centrosome 
separation, spindle assembly, chromosome condensation and Golgi fragmentation. Moreover, 
inactivation of the complex is also necessary to exit from mitosis and occurs upon inactivation of 
the SAC and degradation of Cyclin B by the APC/C, as mentioned before. 
The DNA damage kinases are also involved in the mitotic regulation. Among the kinases 
implicated in the DNA damage checkpoint are included Atm (Ataxia-Telangiectasia Mutated)
 
and 
Atr (ATM and Rad 3-related) and the checkpoint kinases Chk1 and Chk2 (Figure 5). Activation of 
these kinases frequently results in the modulation of mitosis through the regulation of other kinases 
―Wee1 and Myt1, which inactivate Cdks― or phosphatases ―such as the Cdc25 family, which 
activate Cdks by removing the previous inactivating phosphorylations. 
A group of cell cycle kinases are almost exclusively related with mitosis. Included in this 
group of Mitotic Kinases are the kinases of the Polo, Nek and Aurora families participate in the 
centrosome cycle and modulate spindle function and chromosome segregation during mitosis 
(Figure 5). Polo-like kinase (Plk) family is composed by four members in mammals, with Plk1 
being the best known. Plk1 has been implicated in the activation of Cdk1-cyclin B at mitotic entry, 
centrosome maturation, mitotic assembly, the release of cohesin from chromosome arms in 
prophase and in the initiation of cytokinesis (Barr et al., 2004). Regarding the other members of the 
Plk family, Plk2 and Plk3 are mitogen-activated kinases with putative tumor suppressor functions 
and Plk4, the most divergent Plk family member, plays diverse roles in the generation of centrioles 
(Eckerdt et al., 2005; Kleylein-Sohn et al., 2007). The NIMA-related kinase family, or „Nek 
family‟, consist of eleven different members (Nek1–11) (O'Connell et al., 2003). Among them, 
Nek2 is the more deeply characterized member and has been shown to be a core component of the 
human centrosome throughout the cell cycle. Additional kinases such as Bub1, BubR1 and Mps1 
have been shown as major regulators of the spindle assembly checkpoint (Fisk et al., 2004; 
Logarinho and Bousbaa, 2008). Finally, Aurora kinase family includes key regulators of mitosis 
that will be described in detail in the next section. 
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Figure 5. Control of the mammalian cell cycle by phosphorylation. There are three main groups of kinases (in red) that 
regulate cell cycle progression: Interphase’s Cdks, DNA damage kinases and mitotic kinases. The main cell cycle events 
are shown in blue. 
4. The Aurora family of protein kinases 
Early work in Drosophila led to the identification of aurora mutants, which carry a loss-of-function 
mutation in a serine/threonine kinase essential for centrosome separation and the formation of 
bipolar spindles (Glover et al., 1995). A single Aurora protein exists in budding (Ipl1) or fission 
(Ark1) yeast, whereas two family members, Aurora A and Aurora B, are present in worms, flies 
and frogs. Three different Aurora family members, known as Aurora A, B and C, exist in mammals 
(Nigg, 2001). These kinases contain a conserved catalytic domain and N-terminal domains that 
vary in sequence and in length (Figure 6). Aurora B and C are close paralogues that probably arose 
from a relatively recent common ancestor (Brown et al., 2004).  
4.1 Aurora kinases function and localization 
Despite their high level of similarity, the three mammalian Aurora kinases have very distinct 
localizations and functions. 
4.1.1 Aurora A: centrosomes and spindles 
Aurora A, the orthologue to the original Drosophila kinase, localizes on duplicated centrosomes 
from the end of S phase to the beginning of the following G1 phase. Aurora A participates in 
several processes required for building a bipolar spindle including centrosome maturation and  
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Figure 6. Mammalian Aurora kinases. The catalytic kinase domain (light blue) is highly conserved among the three 
mouse aurora kinases. The lysine (K) and aspartate (D) residues (in red) are located in the ATP-binding pocket and are 
in charge of binding to ATP. The T-loop (grey) is located at the activation loop motif (orange). D-box (purple) degradation 
motif is located at the C-terminal end of the three proteins. Outside the kinase domain, the three proteins differ in the 
length of the N-terminal domain in where KEN- and A-boxes degradation motifs are present in Aurora A and Aurora B 
proteins. Aurora B and Aurora C share the biggest homology among them (85% of identity).  
 
separation, mitotic entry and bipolar spindle assembly (Barr and Gergely, 2007; Giet et al., 2005). 
Aurora A is implicated in all these processes through the interaction with a increasing number of 
effectors including Tpx2, Eg5, XMap125/chTog, NDel1, Lats and Tacc proteins. 
4.1.2 Aurora B: the catalytic member of the chromosomal passenger complex 
Aurora B is the enzymatic core of a multiprotein complex, named the chromosomal passenger 
complex (CPC), which comprises other three non-enzymatic subunits, INCENP, Survivin and 
Borealin (Ruchaud et al., 2007) (Figure 7). The CPC localization is highly dynamic. It is initially 
detected along chromosome arms, but is progressively concentrated in inner centromeres through 
prometaphase and metaphase. At the onset of anaphase, the CPC relocates to the central spindle, 
and accumulates at the midbody during telophase and cytokinesis (Figure 7). 
The CPC is one of the most upstream regulators of centromere/kinetochore function being 
responsible for the recruitment to the kinetochore and centromere of a growing number of proteins 
including inner centromeric proteins (Sgo1, Sgo2, Mcak), regulators of the microtubule-
kinetochore interaction (such as Ndc80/Hec1, Cenp-E or Plk1 among others) or proteins involved 
in the Spindle Assembly Checkpoint (SAC; such as Mad2, BubR1 or Mps1) (Kelly and Funabiki, 
2009). Some of these molecules, including Ndc80, Dam1 and Mcak, are Aurora B substrates 
suggesting a critical role for the CPC in the destabilization of aberrant microtubule-to-kinetochore 
attachments and the SAC-dependent delay in mitotic progression until these defects are corrected. 
Recent data suggests that substrate phosphorylation depends on the distance of the substrate from 
Aurora B at the inner centromere, thus indicating that recruitment of the CPC to the kinetochore 
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prevents the stabilization of improper attachments and activates the SAC to delay the metaphase to 
anaphase transition (Liu et al., 2009).  
During cytokinesis, Aurora B is localized to the midbody where its local inactivation is 
crucial for completion of abscission (Guse et al., 2005; Steigemann et al., 2009). Aurora B also 
participates in mitotic phosphorylation of Ser10 and, probably, Ser 28 in histone H3. These events 
seem to be necessary for chromosome condensation although the correlation between H3S10 
phosphorylation and the condensation of chromosomes is not fully established (Johansen and 
Johansen, 2006; Nowak and Corces, 2004; Prigent and Dimitrov, 2003).  
In addition to mitotic roles, Aurora B may also control gene silencing during differentiation 
by displacing heterochromatin protein 1 (Hp1) from facultative heterochromatin and marking 
silent chromatin domains (Amabile et al., 2009; Sabbattini et al., 2007).  
4.1.3 Aurora C: only a male meiotic kinase? 
Less is known about Aurora C, which is expressed at high levels in the testis (Carmena and 
Earnshaw, 2003), and at low levels in thyroid and other cell types (Lin et al., 2006; Ulisse et al., 
2006). Endogenous Aurora C has been detected in meiotic chromosomes of male mouse germinal 
cells where is known to play a specific role in spermatogenesis (Kimmins et al., 2007; Tang et al., 
2006). In agreement with this, mutations in Aurora C have been shown to cause infertility in 
humans (Dieterich et al., 2007). In somatic cells, Aurora C, when exogenously expressed, 
colocalizes with Aurora A during interphase and Aurora B throughout mitosis (Dutertre et al., 
2005) where it can bind members of the CPC (Li et al., 2004). Importantly, Aurora C ectopic 
expression can rescue Aurora B loss of function in cultured cells (Sasai et al., 2004; Slattery et al., 
2009; Slattery et al., 2008; Yan et al., 2005), suggesting that Aurora C can perform the same 
mitotic functions as Aurora B, at least in some cell types. Additional potential roles for Aurora C in 
somatic tissues could include non-mitotic functions such as gene regulation via phosphorylation of 
histone H3 (Price et al., 2009). 
4.2 Regulation of Aurora kinases  
The kinase activity of Aurora family members is controlled by phosphorylation and 
dephosphorylation events, whereas their protein levels are regulated by ubiquitin-mediated 
proteolysis. 
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Figure 7. Aurora B and CPC localization and function during mitosis. Schematic representation of the chromosomal 
passenger complex (CPC) - composed by Incenp, Survivin, Borealin and Aurora B – correlated with its multiple functions 
and different localizations during mitosis. Aurora B substrates in each case are grouped in orange boxes. Aurora B as 
the enzymatic core of the CPC can act as a mitotic chromosome kinase during prophase where it is located along 
chromosomes arms and centromeres. During this stage, it is important for release of arm cohesion, kinetochore 
maturation and probably for chromosome condensation. During prometaphase / metaphase it concentrates in 
centromeres where it is involved in chromosome alignment, the stability of the spindle and the spindle checkpoint. 
Finally, at late mitosis Aurora B translocates to the central spindle where it regulates spindle disassembly and is essential 
for cytokinesis. The CPC during mitosis is shown in green, kinetohores in purple, chromosomes in blue and the mitotic 
spindle in red. Adapted from (Ruchaud et al., 2007). 
4.2.1 Aurora A is regulated by Tpx2 
Aurora A activation depends, in a first place, on the phosphorylarion of a critical threonine residue 
in the T-loop. Although this residue can be phosphorylated in vitro by protein kinase A (Walter et 
al., 2000), it has indeed been identified as an autophosphorylation site (Cheeseman et al., 2002). On 
the other hand, as it was first described in yeast, the phosphatase Pp1 negatively regulates Aurora A 
(Francisco et al., 1994). However, the best known Aurora A regulator is Tpx2 (Kufer et al., 2002). 
Binding with Tpx2 induces a conformational change in Aurora A in such a way that the 
phosphorylated T-loop, inside the activation motif of this kinase, adopts a more compact position, 
providing a better substrate binding platform and hiding the activating phosphoryl group from 
attack by the phosphatase Pp1 (Bayliss et al., 2003). In addition, Tpx2 stimulates 
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autophosphorylation and autoactivation of Aurora A, suggesting that Tpx2 can indirectly regulate 
Aurora A activity (Eyers et al., 2003). Ajuba and Pak1 have also been reported to regulate Aurora 
A activity (Hirota et al., 2003).  
 Aurora A is degraded in an APC/C-Cdh1 dependent-manner during mitotic exit (Castro et 
al., 2002). This mechanism is tightly regulated since D-box degradation motif of Aurora A (Figure 
6) is only functional in the presence of a non-phosphorylated amino-terminal A-box (Littlepage and 
Ruderman, 2002). 
4.2.2 Aurora B is regulated in a CPC-dependent manner 
Aurora B regulation is principally mediated by the interaction with the CPC components: Incenp, 
Survivin and Borealin. Indeed, the CPC members are physically and functionally interpendent in 
that knock-down of any member of the complex delocalizes the others, disrupts mitotic progression 
and may destabilize one or more subunits (Gassmann et al., 2004; Jeyaprakash et al., 2007). The 
CPC non-enzymatic members control the targeting, enzymatic activity and stability of Aurora B 
(Ruchaud et al., 2007) 
Aurora B activation is triggered by autophosphorylation of the T-loop residue after 
association with its substrate Incenp. Full activation occurs also by autophosphorylation in a 
positive feedback loop after Aurora B phosphorylation of Incenp in the conserved IN-box region 
(Bishop and Schumacher, 2002; Honda et al., 2003). In addition, phosphorylation of Borealin by 
Mps1 has been shown to be essential to control Aurora B activity and chromosome alignment 
(Jelluma et al., 2008), revealing a new way to regulate Aurora B activity through a member of the 
CPC and the mitotic kinase Mps1. Althoug some authors have pointed out that Survivin might 
contribute to Aurora B regulation (Bolton, 2002) this possibility has been ruled out by others 
(Honda et al., 2003). Finally, another inner centromere protein, Td-60, has been shown to enhance 
Aurora B activity in the presence of microtubules (Rosasco-Nitcher et al., 2008).  
Aurora B activity is negatively regulated by the action of phosphatases. Although little is 
known about dephosphorylation processes of the CPC, it is thought that, as occurred for Aurora A, 
the major counteracting phosphatase of Aurora B is Pp1 (Emanuele et al., 2008; Francisco et al., 
1994; Hsu et al., 2000). Indeed, Pp1 and Pp1are localized to the outer kinetochore where they 
could be able to remove Aurora B phosphorylation marks (Trinkle-Mulcahy et al., 2006). In 
addition, dephosphorylation of Incenp in budding yeast by Cdc14 phosphatase upon activation by 
separase has been described to be important for the transfer of Aurora B/Incenp to the central 
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spindle (Pereira and Schiebel, 2003). Clearly, dephosphorylation of the CPC and Aurora B 
substrates seems to be crucial for completion of mitosis but needs further study. 
Regarding Aurora B degradation, this kinase is regulated by ubiquitin post-translational 
modifications in different ways. Firstly, Aurora B is targeted by a Cul3-containing SCF ubiquitin 
ligase during early mitosis (Sumara et al., 2007). Interestingly, this modification is necessary to 
remove a fraction of Aurora B from mitotic chromosomes allowing its accumulation on the central 
spindle during anaphase. In the absence of this SCF-Cul3 ubiquitin ligase, Aurora B spreads along 
chromosomes and fails to dissociate from them during anaphase. Secondly, Aurora B requires 
APC/C-Cdh1 activity to efficiently translocate to the spindle midzone in anaphase. Thus, in 
APC/C-Cdh1 depleted cells Aurora B and the CPC are not targeted to the spindle midzone and 
prematurely accumulate in the equatorial cortex resulting in a weak anaphase spindle (Floyd et al., 
2008). Finally, after completion of cytokinesis, the remaining pool of Aurora B is targeted for 
degradation by APC/C-Cdh1 (Floyd et al., 2008; Garcia-Higuera et al., 2008). The requirements for 
the proteolysis of Aurora B by APC/C-Cdh1 are less well understood than in the case of Aurora A, 
but they are likely to involve a KEN-box and a motif similar to the A-box (Nguyen et al., 2005) 
(Figure 6). 
4.2.3 Aurora C, the unknown member of the family 
How Aurora C is regulated is almost completely unknown. It has been described that Aurora C 
interacts with Incenp and therefore, one possibility is that Aurora C activation may also be 
triggered by association with Incenp (Li et al., 2004). Despite the functional similarity between 
Aurora B and Aurora C, both proteins present structural differences in the N- and C- terminal 
domains. For instance, Aurora C do not have the KEN-box and A-box motifs that are present in 
Aurora A and Aurora B proteins (Figure 6), suggesting that Aurora C may be less susceptible to 
degradation than the other Auroras. Supporting this idea, it has been described that Aurora C 
expression in HeLa cells persists after Aurora B degradation near the end of mitosis (Sasai, 2004). 
In addition, the mechanisms by which Aurora C expression is only found in some specific tissues 
remain still undiscovered. 
4.3 Mouse models of Aurora kinases 
Different mouse models have been generated for the study of Aurora A. In three of them Aurora A 
gene has been genetically ablated using different approaches (Cowley et al., 2009; Lu et al., 2008; 
Sasai et al., 2008). Aurora A disruption, in all these cases, leads to early embryonic lethality at 
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embryonic day 3.5 (E3.5) due to severe defects in the formation of the mitotic spindle, indicating 
that Aurora A is an essential regulator of mitosis since the first embryonic divisions. On the other 
hand, different transgenic mouse models have been generated to study the effects of Aurora A 
overexpression in different tissues. In the transgenic models that overexpress Aurora A in the 
mammary gland hyperplasias or malignant tumors were detected after a long latency (Wang et al., 
2006; Zhang et al., 2008a). On the other hand, over-expression of Aurora A in transgenic liver led 
to a low incidence of hepatic tumors (Li et al., 2009).  
 Aurora B has been poorly studied using mouse models. The only transgenic mouse model 
generated and published so far, analyzes the role of Aurora B specifically in spermatogenesis 
(Kimmins et al., 2007). This model, in which expression of either wild-type Aurora B or an 
inactive form of the kinase is driven by a pachytene-stage-specific promoter, confirms the 
important role of Aurora B during male meiosis. 
Aurora C knock-out mouse model has been recently published (Kimmins et al., 2007). 
Aurora C-null mice were viable and appear nearly normal. The unique reported defect is reduced 
male fertility due to morphological defects of the sperm. This mouse model suggests that Aurora C 
appears to play unique functions during spermatogenesis and therefore, it is not required for 
somatic mitosis. 
4.4 Aurora kinases and cancer 
One century ago, Theodore Boveri predicted that chromosome alterations may be associated with 
cancer development and progression. In the last few years, a significant number of genetic 
alterations in mitotic regulators have been described to induce chromosomal instability (CIN) and 
aneuploidy, two related conditions associated with tumour development (Holland and Cleveland, 
2009; Perez de Castro et al., 2007). Given the importance of mitotic kinases in the spindle 
assembly checkpoint, centrosome cycle and chromosomal segregation, it is not surprising that these 
kinases are frequently deregulated in cancer. This fact has opened new therapeutic opportunities to 
battle against cancer by inhibiting mitotic kinases (de Carcer et al., 2007; Perez de Castro et al., 
2008). 
The first data to implicate Aurora family of kinases in tumorigenesis came with the 
observation that Aurora A and Aurora B are overexpressed in primary breast (Bischoff et al., 1998) 
and colon tumour samples (Sen et al., 1997). Importantly, Aurora A has been found to be located 
on human chromosome 20q13, a hotspot of amplification in tumours that has also been associated 
with poor prognosis in patients (Sen et al., 1997). Many subsequent studies identified other tumour 
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types, including breast, pancreatic, ovarian and gastric tumours, in which Aurora A was amplified 
or otherwise overexpressed (Bischoff et al., 1998; Gritsko et al., 2003; Li et al., 2003; Miyoshi et 
al., 2001; Moreno-Bueno et al., 2003; Sakakura et al., 2001; Sen et al., 2002). A third evidence 
came from in vitro studies in which overexpression of wild-type Aurora A, but not a catalytically 
inactive form, is able to cause malignant transformation in primary rodent cells pointing Aurora A 
as an oncogene (Bischoff et al., 1998).  
The role of Aurora B in tumourigenesis is less clear. A recent study, has included both 
Aurora A and Aurora B in the top-70 list of genes of the CIN signature (Carter et al., 2006) 
meaning that they may act as a driving force in tumor initiation (Shih et al., 2001). Some in vitro 
studies have shown that forced expression of wild-type Aurora B, but not a catalytically inactive 
form, can enhance Ras-induced cell transformation (Kanda et al., 2005). Furthermore, 
overexpression of Aurora B in CHO cells was reported to promote aneuploidy and increase 
invasiveness in xenograft experiments suggesting a possible role of Aurora B as a promoter of 
metastasis (Ota et al., 2002).  
Aurora C is also overexpressed in cancer cell lines, but there is just one study that analyzes 
its expression in tumours. In this work, the three Aurora kinases were analyzed in parallel and the 
three of them appear to be overexpressed at the protein level in thyroid carcinomas (Ulisse et al., 
2006).  
All these evidences, have shown Aurora kinases to be promising clinically relevant anti-
cancer targets. Numerous small molecule inhibitors against Aurora kinases have been developed in 
the last years (Taylor and Peters, 2008). The first and best described compounds are Hesperadin, 
VX-680 and ZM447439 (Ditchfield, 2003; Harrington et al., 2004; Hauf et al., 2003). Treatment of 
cells with these inhibitors causes very similar phenotypes than the ones observed upon inhibition of 
Aurora B. All three compounds show a marked decrease in mitotic phosphorylation of histone H3 
on serine 10, accompanied with cytokinesis failure and the appearance of polyploidy cells. In 
addition, VX-680 treatment of mice bearing established xenografted tumours caused significant 
regression of tumour size associated with the induction of apoptosis and reduction of histone H3 
phosphorylation (Harrington et al., 2004). Confirming their potential in anti-tumoral therapies, the 
clinical use of a new generation of Aurora kinase inhibitors is currently being tested in phase I and 
phase II trials (Perez de Castro et al., 2008) (Keen and Taylor, 2009).  
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Aim of the work 
 
The aim of the project presented in this thesis was to determine the relevance of Aurora B in the 
regulation of cell cycle and tumour development in mammals. The work has focused on the 
identification of new regulatory mechanisms of Aurora B and in the functional characterization 
caused by complete or partial inactivation of Aurora B gene in mice and primary cells. 
 
With this intention we proposed the following objectives: 
 
1. Understand the regulation of Aurora B by new posttranslational modifications.  
 
2. Study the consequences of partial inactivation of Aurora B during development and tumor 
formation. 
 
3. Determine the essential roles of Aurora B and putative complementation by Aurora C 
during the first embryonic cell cycles. 
 
4. Explore novel roles of Aurora B using primary cells in which Aurora B can be completely 
eliminated in a conditional manner. 
  
Aim of the work 
 
 
 
22 
 
 
 
Materials & Methods 
 
23 
 
 
 
Materials & Methods 
1. Genetically modified mouse models 
1.1 Animal housing 
All the mice used in this study were housed in the pathogen-free animal facility of the Centro 
Nacional de Investigaciones Oncológicas (Madrid) following the FELASA (Federation of 
European Laboratory Animal Science Associations) recommendations and the current legislation of 
the European Union. All the mice experiments carried out in this memory were previously 
approved by the Bioethics Committee of the Instituto de Salud Carlos III. These animals were 
observed on a daily basis by our specialized technicians (Sheila Rueda and Isabel Moreno) and sick 
mice were killed humanely in accordance with the Guidelines for Humane End Points for Animals 
used in biomedical research. All animals were maintained in a mixed 129/Sv (25%) × CD1 (25%) 
× C57BL/6J (50%) background.  
1.2 Generation of mouse models 
1.2.1 Construction of targeting vectors 
The conditional targeting vector was constructed by Gene Bridges by flanking exons 2-6 of the 
murine Aurkb locus with loxP sequences (Figure 18). The genomic sequences containing Aurora B 
gene were obtained from two bacterial artificial chromosomes (BACs) named RP23-153N12 and 
RP23-26L2. A neomycin resistance-gene (neo
r
) driven by the phosphoglycerate kinase (PGK) 
promoter was used for positive selection of clones.  
The knock-in targeting vector that expresses the -galactosidase (lacZ) gene was constructed 
in our lab using the pFLEx backbone (Schnutgen et al., 2003). Genomic sequences of 5‟ and 3‟ 
homology arms, exons 2-4 and splicing acceptor (SA) were amplified by PCR from previous BACs 
and cloned in the intermediate vectors pCRII-Zero-blunt and pCR4 using the TOPO cloning system 
(Invitrogen). The thymidine kinase gene driven by the PGK promoter (PGK-TK cassette) was 
amplified from pPNT vector (Tybulewicz et al., 1991) and was used for negative selection of 
clones after ganciclovir addition. The SA was then cloned in pFLEx using PmeI/PmeI restriction 
sites, exons 2-4 were cloned in NruI/NruI, the 5‟ arm in NotI/XhoI, the 3‟arm in SalI/SalI and the 
PGK-TK cassette in MfeI/MfeI.  
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The knock-in targeting vector that gives inducible expression of Aurora B gene under a 
minimal tetracycline promoter was constructed in collaboration with Earnshaw‟s lab in Edinburgh 
using a modified version of pTRE-tight vector (Clontech). This modified pTRE-tight vector 
contains the puromycin gene sequences driven by the -actin promoter for positive selection of 
clones. Genomic sequences of 5‟ and 3‟ homology arms, were amplified by PCR from previous 
BACs and cloned in pGEM-T (Promega) intermediate vector. The cassette PGK-TK was amplified 
from pPNT vector and was used for negative selection of clones. The 5‟arm was then cloned in 
pTRE modified vector using AvrII/SpeI restriction sites, the 3‟arm was cloned in PvuII/NotI and 
the PGK-TK cassette in ClaI/ClaI. 
1.2.2 Generation of quimeras 
To facilitate homologous recombination, mouse ES cells V6.4 obtained from a hybrid (129 x 
C57BL/6J) strain were electroporated with 100ug of linearized DNA from the corresponding 
targeting vectors. Recombinant ES cells and clones were selected in the presence of G418 
(neomycin) and, if possible, with ganciclovir. This step was done by the Transgenic Unit of the 
CNIO. The identification of the recombinant clones was performed by Southern blot analysis using 
new restriction sites from the recombinant alleles and probes external to the homology arms. 
Positive recombinant clones were either aggregated with morulas CD1 or microinjected into 
C57BL/6J blastocysts by the Transgenic Unit of the CNIO. The male quimeras obtained (Figure 8) 
were crossed with wild-type females for transmission of the recombinant allele. 
1.2.3 Generation of Aurora B conditional, knock-in and null alleles  
Heterozygous recombinant mice Aurkb(+/loxfrt) (conditional knock-out model) and 
Aurkb(+/Zloxfrt) (knock-in model) were first crossed with TgpCAG–Flpe transgenic mice 
(Rodriguez et al., 2000) that ubiquitously expressed Flp recombinase, to remove the neo selection 
marker and thus, to generate either the conditional Aurkb(lox) allele (conditional knock-out model) 
 
 
Figure 8. Generation of quimeras. (a) 
Quimeras (arrows) obtained from 
aggregation of ES cells (129/ C57BL/6J 
– agouti/black) with morulas (CD1 – 
white). (b) Quimeras (arrows) obtained 
from microinjection of ES cells (129/ 
C57BL/6J – agouti/black) into 
blastocysts (black). 
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or a non-functional conditional Aurkb(Zlox) allele (knock-in model). To generate the null alleles, 
we crossed Aurkb(+/lox) mice and Aurkb(+/Zlox) with TgCMV–Cre transgenic mice (Schwenk et 
al., 1995) that ubiquitously expressed Cre recombinase. In the Aurkb(lox) allele, Cre-mediated 
recombination between the two loxP sites excises exons 2-6; whereas, in the Aurkb(Zlox) allele, 
Cre-mediated recombination between the two wild-type loxP sites, or between the two mutant 
lox511 sites, eliminates exons 2-4 and produces an inversion of the IRES (internal ribosome 
binding site)-lacZ cassette. In the final Aurkb(Z) allele, the IRES-lacZ cassette is transcribed 
downstream the Aurkb exon 1 resulting in a truncation of the Aurkb transcript and expression of -
galactosidase from the IRES. 
On the other hand, heterozygous recombinant mice Aurkb(+/lox-tet) were crossed with 
TgCMV–Cre transgenic mice to remove the puromycin selection cassette, obtaining the final 
Aurkb(tet) allele. 
Table 1. Genetic modifications of Aurora B locus. 
Aurora B alleles Description 
Aurkb(lox) Conditional allele 
Aurkb(–) Null allele , germline deletion 
Aurkb() Null allele, deletion by adenovirus infection of Cre 
Aurkb(Z) Knock-in allele, Aurkb gene is replaced by lacZ transcripts 
Aurkb(tet) 
Knock-in allele, Aurkb promoter  is replaced a minimal 
tetracycline inducible CMV promoter 
1.3 Mouse crosses  
The mouse strains shown in Table 2, were crossed at some point with the different mouse models 
generated for Aurora B. 
Table 2. Mouse strains used in this study. 
Mouse line Description Origin 
TgCMV-Cre Transgenic line expressing Cre recombinase under ubiquitous 
CMV promoter 
(Schwenk et al., 1995) 
TgpCAG–Flpe Transgenic line expressing the Flpe recombinase under the 
control of the pCAG element (beta-actin promoter-CMV 
enhancer) 
(Rodriguez et al., 2000) 
TgMMTV-
Erbb2 
Transgenic line expressing the activated rat Erbb2 (c-neu) 
oncogene under the direction of the mouse mammary tumor 
virus promoter  
Jackson Laboratories 
(Muller et al., 1988) 
Rosa26-
M2rtTA 
Knock-in line expressing a reverse tetracycline-controlled 
transactivator (rtTA) 
(Beard et al., 2006) 
1.4 Mouse genotyping  
For genotyping Aurkb(lox), Aurkb(–) , Aurkb(Z) and Aurkb(tet) alleles we isolated tail DNA from 
3-4-week old mice and we performed a PCR amplification reaction using the oligonucleotides 
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shown in Table 3 and following this conditions: 94 ºC during 4 minutes followed by 35 cycles of 
DNA denaturalization at 94 ºC during 30seconds, primer annealing at 60 ºC during 30 seconds and 
polymerase extension at 72 ºC during 60 seconds ending with a single elongation cycle of 7 
minutes at 72 ºC.  
Table 3. Oligonucleotides used for Aurkb locus genotyping. (cKO:conditional knock-out, F:forward 
and R, reverse primers, asterisk (*) indicates size too big for genotyping purposes). 
Mouse Model Name Sequence (5’-3’) Aurkb allele and size 
cKO F-1 
R-3 
AGAGGTCTCCCTGCCTCTG 
GGGCATGAATTCTTGAGTCG 
Aurkb(+) :   1520bp* 
Aurkb(–) :   364bp 
cKO F-2 
R-3 
AGGGCCTAATTGCCTCTTGT 
GGGCATGAATTCTTGAGTCG 
Aurkb(+) :   358bp 
Aurkb(lox) : 491bp 
lacZ knock-in  F-Z1 
R-Z2 
AGAGGTCTCCCTGCCTCTG 
GGAGCAAAGGGTGACTCTGA 
Aurkb(+) :   247bp  
Aurkb(Z) :   435bp 
tet knock-in  F-Tet1 
R-Tet2 
AGTAGTCTCTGCCCCCTGGT 
GAGATGGGTTGGGTAGCAGA 
Aurkb(+) :   482bp  
 
tet knock-in F-Tet1 
R-Tet3 
AGTAGTCTCTGCCCCCTGGT 
GCCTCGTGATACGCCTATTT 
Aurkb(tet) : 368bp 
1.5 Treatments in live animals 
1.5.1 Wound healing 
To analyze the ability of Aurkb(+/+) and Aurkb(+/–) mice to repair wounds we introduced 4-mm 
punch biopsy wounds into the dorsal skin of anesthetized mice. We performed two wounds per 
mouse, one per flank. For a period of five days, we measured wound diameters using a digital 
caliper and we took pictures of all the wounds. We repeated the same protocol to collect skin 
samples from wounded-mice for immunohistochemistry and hispathological analysis.  
1.5.2 Hepatectomy 
To study the ability of hepatocytes to enter the cell cycle and regenerate the liver after tissue loss 
we performed 2/3 partial hepatectomy following the guidelines described in (Mitchell and 
Willenbring, 2008). The mass of the resected liver tissue was measured after the operation, and that 
of the remnant liver was determined after killing of the animals six days after surgery. After 
hepatectomy, Aurkb(+/+) and Aurkb(+/–) mice were injected intraperitoneally (i.p) with 50mg/kg 
BrdU (Sigma) 2 h before mice were sacrificed for samples. This surgery was done in collaboration 
with Dr. Cristopher Heeschen.  
1.5.2 Tumor induction 
1.5.2.1 Skin carcinogenesis: DMBA-TPA 
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Seven-day-old Aurkb(+/+) and Aurkb(+/–) mice were painted with a single dose of 0.5 mg of 7,12-
dimethylbenz[]anthracene (DMBA). Two weeks later, tumor growild-typeh was promoted by 
treating with 5 mg of 12-O-tetradecanoylphorbol-13-acetate (TPA) twice a week for twelve weeks. 
Mice were shaved before each treatment to allow a better distribution of the chemicals. Animals 
were observed on a daily basis, and the size and characteristics of the skin lesions were annotated. 
Tumors were measured weekly in two using a digital caliper. Most mice developed multiple 
lesions. The position and number of each tumor were recorded, and each lesion was followed 
individually. 
1.5.2.2 Fibrosarcomas: 3-methylcholanthrene (3-MC) 
For the induction of fibrosarcomas Aurkb(+/–) and Aurkb(+/+) mice of 3–5 months of age, received 
a single intramuscular injection, in one of the rear legs, of a 50 µl solution containing 3MC 
(Sigma), at a concentration of 20 µg/µl, and dissolved in sesame oil (Sigma). Mice were observed 
on a daily basis until tumors of >1.5 cm in diameter developed in the injected leg, at which point 
the animals were killed humanely and the tumors were extracted for further analysis. 
2. Histological and immunohistochemical analysis 
For histological observation, dissected organs were fixed in 10%-buffered formalin (Sigma) and 
embedded in paraffin wax. Sections of 3- or 5-μm thickness were stained with haematoxylin and 
eosin (H&E). Additional immunohistochemical examination of the tissues and pathologies 
analysed were performed using the antibodies noted as IHQ that are shown in the Table 4. 
The quantification of DNA ploidy in sections was performed using ImageJ software 
(National Institutes of Health, Bethesda, Maryland, USA, http://rsb.info.nih.gov/ij/). The pathology 
analysis was performed by Marta Cañamero, head of the Comparative Pathology Unit of the CNIO. 
3. Embryos 
3.1 Embryo culture and extraction 
Zygotes were extracted by ripping the ampula of pregnant females from crosses between Aurkb(+/–
) mice. The zygotes obtained were then treated with hyalurodinase (Sigma) to remove the cumulus 
cells and washed with Hepes-buffered Medium 2 (M2; Sigma). Fertilized embryos at E1.5-E2.5 
were collected by flushing the uteri of pregnant females with M2 (Sigma). Zygotes and embryos 
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Table 4. Primary antibodies used in different assays. (IHQ: immunohistochemistry ; IF: immunofluorescence ; IP: 
immunoprecipitationWB: Western-blot). 
Antibody Host Species/Clonality Application Dilution Source / Clone 
ACA  Human Polyclonal IF 1:100 Antibodies Incorporated 
Akt Rabbit Polyclonal WB 1:500 Cell Signaling 
-tubulin Mouse Monoclonal IF, WB 1:2000 Sigma / DM1A 
-tubulin Rat Monoclonal IF 1:1 ATCC / YL1/2  
Aurora B Mouse Monoclonal IF, WB 1:200 BD Transduction / AIM-1 
Aurora B Rabbit Polyclonal IF, IHQ 1:200/1:100 Abcam 
Aurora C Rabbit Polyclonal IHQ 1:250 Zymed 
-Actin Mouse Monoclonal WB 1:2000 Sigma / AC-40 
Bromo-deoxyuridine Mouse Monoclonal IF 1:50 BD Pharmingen / 3D4 
Bromo-deoxyuridine Mouse Monoclonal IHQ 1:50 GE Healthcare / BU-1 
Caspase 3 Active Rabbit Polyclonal IHQ 1:200 RYD Systems 
Cyclin B1 Mouse Monoclonal IHQ 1:175 Millipore / U152 
Cyclin B1 Rabbit Polyclonal IF 1:200 Santa Cruz Biotech. 
-tubulin Mouse Monoclonal IF 1:500 Sigma / GTU88 
HA Rabbit Polyclonal WB 1:4000 Abcam 
Incenp Human Polyclonal IF 1:100 Hospital Puerta del Mar 
Ki67  Rat Monoclonal IHQ 1:100 GE Healthcare  
Mad2 Rabbit Polyclonal IF 1:500 E. Salmon laboratory 
p21Cip1  Mouse Monoclonal WB 1:100 Santa Cruz Biotech. 
Phospho-CENP-A (Ser7) Rabbit monoclonal IF 1:200 Upstate Biotech. / NL41 
Phospho-Histone H2A.X (Ser139) Mouse Monoclonal IHQ 1:2000 Millipore / JBW30 
Phospho-Histone H3 (Ser10) Rabbit Polyclonal IF 1:500 Upstate Biotechnology 
Phospho-p53 (Ser15) Rabbit Polyclonal IHQ 1:25 Cell Signaling 
Phospho-P70-S6K (T389) Mouse Monoclonal WB 1:500 Cell Signaling / 1A5 
Phospho-Rb (S780) Rabbit Polyclonal WB 1:500 Cell Signaling 
V5 Mouse Monoclonal IF, IP 1:2000/1-2ug Invitrogen 
 
were cultured in vitro in potassium simplex optimized medium (KSOM, Chemicon International 
Inc.). Embryos were treated with the Aurora kinase inhibitor ZM447439 (Tocris, Biosciences) at a 
2 or 20 M final concentration of the drug during 12 hours. To perform embryo “hatching”, 
blastocyts were transferred into gelatinized p96-well plates and cultured in ES cells medium 
(DMEM+GlutaMAX, 15% fetal bovine serum, non-essential aminoacids) for several days. This 
process can be visualized in Figure 9. 
 
Figure 9. Culture of blastocysts – Embryo “hatching”. A blastocyst at E4.5 display a clear inner cell mass (ICM) a layer of 
trophoblast cells (T) and it is surrounded by a thick membrane called zona pellucid (zp). After one day in culture the 
blastocyst’s growild-typeh starts to deform the zp until it finally breaks (E6.5). At this moment, the embryo attaches to the 
plate with the help of a cell lineage derived from the trophoblast called trophoblast giant cells (TGC). Once attached, and 
after several days in culture (E7.5-E10.5) the blastocyst’s ICM form a robust mass of ES cells surrounded by a big 
population of TGC. 
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3.2 Embryo microinjection 
For RNA interference against Aurora B and C in early embryos, wild type zygotes were 
microinjected with a combination of three distinct shRNAs for each kinase that were cloned in a 
modified Gateway® (Invitrogen) compatible version of pSuper-Retro plasmid, along with a 
reporter H2B-GFP expression vector at a final concentration of 20ng/ul. Forty eight hours after 
microinjection, embryos were observed under the confocal microscope to confirm H2B-GFP 
expression and then fixed for immunostaining or maintained in culture one day more. At 72h after 
microinjection, embryos were used for RNA extraction or fixed for immunostaining. The targeted 
sequences for Aurora B and C are shown in Table 5. Embryo microinjection was performed by 
Javier Martín (Transgenic Unit, CNIO) 
Table 5. siRNA sequences to interfere against Aurora B and Aurora C. 
Vector Target sequence (5’-3’) 
shAurkb-1 GTTGGCTGAGAACAAGAGT 
shAurkb-2 GAGCCGTTTCATCGTGGCA 
shAurkb-3 CAAGAGTCAGGGCTCCACT 
shAurkc-1 GGAAAATCATTTCATCGTG 
shAurkc-2 CCAGGAAGCATTTCACCAT 
shAurkc-3 GCTTCTTAGGTACCATCCT 
4. Cell culture 
4.1 MEFs culture, extraction and infection  
Mouse embryonic fibroblasts (MEFs) were prepared from E14.5 embryos and cultured using 
standard protocols. E14.5 embryos were extracted from the uterus of pregnant females from 
Aurkb(+/–) intercrosses, the placenta was removed and embryos were isolated from the yolk salk. 
The embryo without the liver and the head was minced, and dispersed in 0.1% trypsin (5 min at 
37C). Cells were grown for two population doublings and then frozen. All cultures were 
maintained in Dulbecco‟s modified Eagle‟s medium (DMEM; Gibco) supplemented with 2 mM 
glutamine, 1% penicillin/streptomycin and 10% foetal bovine serum (FBS). To analyze S phase 
entry, passage 2 MEFs (10
6
 cells per 10 cm dish) were deprived of serum for 48 hr and 
restimulated with 10% FBS to enter the cell cycle. MEFs were pulsed for 30 min with 10 M BrdU 
and stained using an anti-BrdU antibody (BD Pharmingen). BrdU incorporation was measured by 
immunofluorescence and DNA content. MEFs infection was performed using adenoviruses 
expressing GFP or the Cre recombinase (Ad5 CMV-Cre) obtained from The University of Iowa 
(Iowa City, IA). Infection was carried out during 2 days in a cell culture synchronized in G0 by 
serum deprivation and/or confluence.  
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4.2. Human and mouse cell lines 
HEK293, U2OS and HeLa human cells were maintained in DMEM medium supplemented with 10 
% fetal bovine serum and antibiotics and were grown at 37ºC in a humidified 5% CO2 atmosphere. 
NIH-3T3 mouse cells were maintained in the same conditions with 10% calf serum. Human Aurora 
B was silenced using validated siRNA oligos from Qiagen with the following sequence: 5‟- 
AACGCGGCACTTCACAATTGA-3‟. HEK293, U2OS and HeLa cells were transfected with 1 g 
of plasmid DNA using Effectene transfection reagent (Qiagen) according to the manufacturer´s 
instructions. For silencing experiments, siRNA oligos were nucleofected in HeLa cells using 
Amaxa kit and the conditions provided by Amaxa I13 program. In focus formation assays, NIH-
3T3 cells were transfected with 10ug of V5-Aurora B plasmids and 1ug of HRasG12V following 
standard calcium phosphate transfection protocol, maintained in culture during three weeks and 
then stained with crystal violet solution for foci quantification.  
Cell cycle distribution of MEFs and human cell lines were determined by flow cytometry 
after DNA staining with propidium iodide (Sigma) and analysed on a FACSCanto flow cytometer 
(Becton Dickinson). Data were processed using FACSDiva software (Becton Dickinson). MEFs 
and HeLa cells were treated with ZM447439 (Tocris, Biosciences) at a 2M final concentration of 
the drug 
5. Biochemical procedures 
5.1 RNA extraction and Real-time-PCR 
To quantify expression of Aurora transcripts, total RNA from embryos at different stages was 
isolated using Trizol (Invitrogen). Expression of Aurora B and Aurora C was quantified by real-
time quantitative amplification with the SuperScript® III Platinum assay kit (Invitrogen), according 
to the manufacturer‟s instructions, in a BioRad iCycler Real-Time PCR apparatus. Amplification of 
GAPDH was used for normalization. The oligonucleotides used for amplification of Aurora B, 
Aurora C and GAPDH are shown in Table 6.  
Table 6. Oligonucleotides used for RT-PCR of Aurora B and Aurora C (F, forward and R, reverse primers). 
RT-PCR Oligos Target sequence (5’-3’) 
Aurkb-F ATGGCTCAGAAGGAGAACGC 
Aurkb-R CCAGTTCCCACCCCTTCT 
Aurkc-F ATGGAGCCCAGCACCTCAAC 
Aurkc-R ACAGAGCCTGGAGACCTTCC 
GAPDH-F GCCACCCAGAAGACTGTGGATGGC 
GAPDH-R CATGATGGCCATGAGGTCCACCAC 
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5.2 DNA cloning 
Mouse Aurora B cDNA was amplified by PCR from the plasmid mAA0155 (Mammalian Gene 
Collection), cloned into pENTR-D-TOPO vector using TOPO technology (Invitrogen) and 
transferred to a destiny vector coexpressing GFP or V5 tag by a LR recombination reaction of the 
Gateway system (Invitrogen). Aurora B mutants (K111M, D205A and K207R) were prepared 
using the Quick-Change site-directed mutagenesis kit (Stratagene) and were verified by DNA 
sequencing. The additional plasmids pcDNA3.1-HA-SUMO-1,/-2 and /-3 and pcDNA3-Ubc9 were 
kindly provided by Ron Hay (Wellcome Trust Centre for Gene Regulation and Expression, 
Dundee, UK); whereas, HRas-G12V expression vector was from Barbacid‟s laboratory (CNIO). 
5.4 Immunofluorescence 
For immunofluorescence, embryos were fixed with cold methanol during 1 h at –20ºC, rinsed with 
M2 medium, washed in PBS containing 0.1% BSA (Sigma) and incubated with 0.1% Triton X for 
permeabilization. Alternatively, embryos were fixed with 5% paraformaldehyde (PFA). MEFs and 
human cell lines were fixed with 4% PFA and permeabilized with 0.15% Triton X.  Embryos or 
MEFs were then blocked with 3% BSA and incubated with the primary antibodies noted as IF that 
are shown in Table 4. The matching secondary antibodies, with different Alexa dies (488, 594, 
647), are from Molecular Probes (Invitrogen). Images were obtained using a confocal ultra-spectral 
microscope (Leica TCS-SP5). 
5.4 X-Gal detection in embryos and cells 
To detect -galactosidase activity, embryos were fixed for 5 min in PBS containing 1% 
formaldehyde, 0.2% glutaraldehyde and 1% serum. After fixation, embryos were rinsed with 1% 
serum in PBS and then transferred to a -galactosidase reaction mixture (4 mM K3Fe(CN)6, 4 mM 
K4Fe(CN)6, 2 mM MgCl2 and 1 mg/ml X-gal in PBS) at 37ºC overnight. Embryos were washed 
once in PBS and kept at 4ºC. Positive embryos were scored 48h after the reaction was initiated. 
Alternatively, ES cells were fixed with 0.2% glutaraldehyde and treated overnight at 37ºC with the 
same -galactosidase reaction mixture. 
5.5 Protein extraction and analysis  
For immunodetection in protein lysates, cells were washed twice with ice-cold PBS and lysed in 
RIPA lysis buffer (37 mM NaCl, 0.5% NP-40, 0.1% SDS, 1% TX-100, 20 mM Tris-HCl pH 7.4, 2 
mM EDTA, 10% glicerol 1 mM PMSF) supplemented with protease and phosphatase inhibitory 
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cocktails (Sigma). Additionally, for detecting SUMOylated proteins an inhibititor of SUMO-
proteases, called N-ethylmaleimide (NEM), was added at 10mM final concentration. After 30 min 
on ice, samples were cleared by centrifugation. Proteins were separated on SDS-PAGE, transferred 
to nitrocellulose membranes (BioRad), probed using specific antibody and detected using 
fluorescent donkey (Rockland) or goat (Invitrogen) anti rabbit or anti mouse secondary antibodies 
followed detection using the Odyssey Infrared Imaging System (Li-Cor Biosciences). After transfer 
of the protein lysates, we probed nitrocellulose membranes with primary antibodies noted as WB 
that are shown in Table 4. Secondary antibodies were coupled to Alexa 680 and 800 dies 
(Invitrogen) for immunodetection. 
5.6 Immunoprecipitation and in vitro kinase assays 
Total protein lysates extracted from HEK293 cells transiently transfected with V5-tagged Aurora B 
vectors were precleared with protein G-agarose bead suspension for 1hour (Amersham). 
Supernatants were first incubated for 2h at 4ºC on a rotating wheel with mouse anti-V5 (Invitrogen) 
and later with 50 l of the blocked bead suspension for an additional hour. Immunoprecipates were 
then washed three times in RIPA buffer and, in case of the kinase assay, one extra wash was 
performed with RIPA plus 0.5M NaCl to remove possible bound unspecific kinases. One fifth of 
the immunoprecipitates bound to the beads were used for V5 detection by western blot. For the 
kinase assay, four fifths of the beads were washed in kinase assay buffer [10 mM HEPES-NaOH 
(pH 7.4), 150 mM NaCl, 10 mM MgCl2, and 1 mM EGTA] supplemented with 0.5 mM DTT and 
phosphatase inhibitor cocktail (Calbiochem) and later incubated in 25 µl of 2x kinase buffer 
supplemented with 0.2 mM ATP, 2,5 uCi [-32P]ATP and 3 ug of MBP as Aurora substrate. The 
reactions were incubated for 30 min at 30° C, stopped by addition of 5 µl of 5x Laemmli sample 
buffer, separated on a 12.5 % SDS-PAGE and analyzed by autoradiography. 
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Results 
1. SUMO regulation of Aurora B 
1.1 Aurora B is modified by SUMO 
Aurora B regulation is principally mediated by the interaction with the CPC components: Incenp, 
Survivin and Borealin. Recent work has emphasized the importance of post-translational 
modification for proper activity and control of the dynamic behavior of the CPC. For example, 
phosphorylation of Borealin by Mps1 kinase is essential to activate Aurora B (Jelluma et al., 2008); 
ubiquitination controls the dynamic association of Survivin and Aurora B to the chromatin 
(Ramadan et al., 2007; Vong, 2005); and SUMOylation has been very recently shown to modified 
Borealin (Klein et al., 2009).However, the participation and the functional impact of these and 
other post-translational regulatory mechanisms of Aurora B remains to be elucidated. 
1.1.1 Identification of a putative SUMOylation motif conserved in Aurora B proteins  
To find new regulatory mechanisms of Aurora B we performed an in silico bioinformatic analysis 
of this kinase. We first used ELM (Eukaryotic Linear Motif, http://elm.eu.org) site prediction 
software that predicts the presence of 136 motifs in the sequence of a given protein. These motifs 
among other functions, promote protein-protein interactions, are recognized for post-translational 
modifications and regulate protein transport. In mouse Aurora B protein sequence we identified 
motifs already described in the regulation this kinase, thus validating the in silico analysis. This 
motifs are emphasized in a black box in figure 10a and are responsible for Aurora B degradation 
(KEN-box and D-box motifs), and Aurora B activity (PP1 binding motif). Interestingly, a 
consensus motif for SUMO modification (-Lys-X-Glu, in which  means hydrophobic 
aminoacid residue and X any residue) that has not been previously related with Aurora B, is present 
in the kinase domain (Figure 10a, red box). To further confirm the presence of this motif we used 
the specific SUMO prediction software SUMOplot™ Analysis Program, 
(http://www.abgent.com/tools/SUMOplot) and we identified the same consensus motif for SUMO 
modification.  
To evaluate the importance of SUMO motif in Aurora B regulation, we analysed the 
evolutionary conservation of this motif among Aurora B orthologues (Figure 10b). Importantly, the 
Aurora B sequence I-K-P-E (Ile – Lys – Pro – Glu) that constitutes the SUMO motif is completely 
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Figure 10. Identification of a putative SUMOylation motif conserved in Aurora B proteins. (a) Bioinformatic analysis of 
mouse Aurora B protein using ELM (Eukaryotic Linear Motif Resource for Functional Sites in Proteins: http://elm.eu.org) 
site prediction program. At the top of panel (SMART/Pfam line) appears in dark green the prediction of Aurora B kinase 
domain. The next line (GlobPlot) predicts a central region of globularity (light green) within Aurora B, flanked by 
disordered regions (orange). Then, the secondary structure is predicted based on the presence of -helixes (yellow) and 
-strands (light brown). Finally, the predicted motifs (blue, gray or partial red) are shown in the following lines. The motifs 
already described to regulate Aurora B are inside a black rectangle (D-box and KEN-box motifs regulate Aurora B 
degradation and PP1 binding regulate its activity). An interesting non-described motif, recognized for modification by 
SUMO peptides, is contained in a red rectangle. For a detailed description of each motif visit: 
http://elm.eu.org/browse.html (b) Multiple sequence alignment of Aurora B proteins from different species (Mm: Mus 
musculus ; Rn: Rattus norvegicus ; Hs: Homo sapiens ; Xl: Xenopus laevis ; Dm: Drosophila melanogaster ; Ce: 
Caenorhabditis elegans ; Sc: Saccharomyces cerevisiae) using ClustalView software (http://www.ch.embnet.org). SUMO 
modification motif (black asterisk) is highly conserved in Aurora B proteins, as well as in Aurora kinases, but it is not 
present in the closest mitotic relatives of these mitotic kinases (PLK4 proteins). Note that the SUMO motif is located one 
residue downstream the aspartate residue (D205, grey arrow) that binds to ATP.   
 
conserved in all Aurora B orthologues from yeast to human (Figure 10b). The SUMO motif is also 
present in the other mammalian members of the Aurora family but not in the closest mitotic kinases 
(Plk family). 
1.1.2 Aurora B mouse protein is SUMOylated at K207 residue  
To confirm whether the SUMOylation site of Aurora B corresponds to the predicted lysine residue 
(K207 in mouse), we mutated this residue into the charge-conservative arginine residue. K207R 
mutation impedes SUMO covalent binding affecting as less as possible the kinase structure. Next, 
we expressed V5 epitope tagged versions of mouse Aurora B wild-type and K207R mutant along 
with an Ubc9 expression vector and HA-tagged versions of the three SUMO isoforms by transient 
transfection of HEK293 cells (Figure 11). The ectopically expressed proteins were 
immunoprecipitated using -V5 antibodies, and detected by western-blotting with an antibody 
Results 
 
35 
 
 
 
directed against HA epitope. Consistant with our previous hypothesis we detected a band at the 
predicted SUMO-Aurora B conjugate size of 50 kDa when the three SUMO isoforms were 
expressed (Figure11, double asterisk). Importantly, SUMO-Aurora B conjugates were only present 
in cells expressing the non-mutated Aurora B form demonstrating that K207 residue is required for 
SUMO covalent modification of Aurora B. 
 
Figure 11. In vivo SUMOylation of Aurora B at K207 
residue. HEK293 asynchronous cells were transiently 
transfected with V5-Aurkb-WT/-K207R, HA-SUMO-1/-2/-
3 and E2-ligase Ubc9 expression vectors. Transfection 
with the empty pDEST-V5 vector was used as negative 
control. V5-Aurora B proteins were immunoprecipitated 
48h after transfection using -V5 antibodies and 
immunoblotted with -HA and -V5 antibodies. -HA 
western blotting shows detection of Aurora B-SUMO 
conjugates (double asterisk) in the cells transfected with 
V5-Aurkb-WT at approximately 50 kDa, which is the 
expected size for V5-Aurora B-HA-SUMO1/2/3, and not 
in the cells transfected with V5-Aurkb-K207R mutant 
form.-V5 western blotting detects V5-Aurora B 
immunoprecipated proteins in all lanes (single asterisk) 
and an additional band (double asterisk) only present in 
the V5-Aurkb-WT transfected cells that corresponds to 
the SUMO-modified V5-Aurora B form. The mouse IgGs 
are shown as triple asterisk.  
1.2. Ectopic expression of a SUMO-dead Aurora B protein induces cellular defects 
1.2.1 Lack of Aurora B SUMOylation at K207R induces polyploidy and nuclear defects  
To address whether SUMOylation of Aurora B is important for cell cycle progression, we 
transiently transfected HEK293 cells with GFP tagged vectors for Aurora B wild-type, putative 
kinase-dead mutants (K111M and D205A) and a SUMO-dead form (K207R). As previously 
described (Tatsuka, 1998), over-expression of Aurora B wild-type slightly increases the percentage 
of 4N and >4N cells indicating mitotic arrest and defects in completion of cytokinesis. These 
defects are more pronounced upon the expression of Aurora B K111M kinase-dead mutant and, 
even at a higher degree, after expression of Aurora B D205A kinase-dead mutant where a dramatic 
increase in the >4N cell population is also observed (47.6% of >4N GFP-AurkB-D205A cells vs. 
19.1% of >4N GFP-AurkB-K111M cells, Figure 12b). This phenotypic difference between K111M 
and D205A mutants may suggest distinct grades of inhibition of kinase activity and/or kinase-
independent defects in D205A mutant. Interestingly, over-expression of a SUMO-dead Aurora B 
protein (K207R) induces polyploidy at the same level as D205A mutant (44.1% of >4N GFP-
AurkB-K207R cells vs. 47.6% of >4N GFP-AurkB-D205A cells, Fig 12b). A more detailed  
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Figure 12. Transient expression of Aurora B K207R mutant form induces poliploidy and nuclear defects. (a) DNA content 
histograms of HEK293 cells transiently transfected with a GFP empty vector (EV) and GFP tagged vectors for Aurora B 
wild-type and Aurora B mutants – K111M, D205A and K207R – and fixed 72h after transfection. HEK293 GFP-positive 
cells were cytometry detected and used for cell cycle analysis. Over-expression of a SUMO-dead Aurora B protein 
(K207R) deregulates cell cycle progression inducing polyploidy in the same way as D205A kinase-dead form.  (b) Bar 
graph quantification of cellular DNA content, showing a dramatic increase of polyploidy in cells overexpressing Aurora B-
D205A and -K207R mutants. (c) Immunofluorescence collection of images obtained with the Olympus ScanR system 
revealing that cells over-expressing Aurora B-K207R mutant are mostly multinucleated and display nuclear aberrancies. 
 
examination of these cells using the Olympus ScanR system allowed us to determine that the >4N 
cells over-expressing K207R mutant are mostly multinucleated and display severe nuclear 
abnormalities (Figure 12c). 
1.2.2 Lack of Aurora B SUMOylation compromises cell viability 
We next analyzed the cellular consequences of stably expressing Aurora B K207R in a long-term 
manner. For this purpose, we transfected U2OS cells with a GFP-empty vector and the previously 
described GFP-tagged vectors for Aurora B forms (wild-type, K111M, D205A and K207R) and we 
cultured GFP-positive cells with G418 selection during 12 days (Figure 13a). Stable expression of 
D205A and K207R in these cells severely reduces the number of colonies suggesting that 
mutations in these residues impair Aurora B function in a way that it is incompatible with cell 
viability (Figure 13b). A detailed inspection of these colonies reveals that expression of K207R 
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mutant promotes polyploidy, cellular fragmentation and cell death (Figure 13c). The presence of 
these poliploid cells is consistant with the cell cycle defects observed upon GFP-Aurora B-K207R 
transient expression (Figure 12). In addition, GFP-Aurora B-K207R colonies display bigger mitotic 
cells and less cytokinesis bridges than GFP-Aurora B-wild-type colonies suggesting abnormal 
mitosis and defects in completion of cytokinesis (Figure 13c). 
1.3. Aurora B is regulated by SUMO 
Deregulation of Aurora B function by chemical inhibition, small interference RNA (siRNA) 
treatment or overexpression of a kinase-dead form leads to very similar phenotypes including 
chromosome misalignment with subsequent arrest in prometaphase and fail to execute cytokinesis 
resulting in multinucleated cells (Ruchaud et al., 2007). To gain insight into the role of 
SUMOylation in Aurora B regulation, we generated and analyzed HeLa stable cell lines for GFP-
Aurora B-WT /-D205A and /-K207R fusion proteins. 
 
 
 
Figure 13. Stable expression of Aurora B K207R mutant form compromises cell viability. (a) Colony formation assay of 
U2OS cells stably expressing GFP empty vector (EV) and GFP tagged vectors for Aurora B (wild-type, K111M, D205A 
and K207R). U2OS GFP-positive cells were sorted 48h post-transfection, replated in the presence of G418 1mg/ml, then 
fixed 12 days later and stained with crystal violet to determine colony number. 50*103 GFP-positive cells were sorted and 
plated per p100. (b) Bar graph quantifying the number of macroscopic colonies per p100 plate showing a clear reduction 
of colonies in cells expressing Aurora B-D205A and -K207R mutants. (c) Representative colonies stably expressing 
GFP-Aurora B-WT and GFP-Aurora B-K207R. Colonies expressing GFP-Aurora B-K207R mutant present multinucleated 
cells (light blue open arrows), cellular fragmentations (light blue arrow) and dead cells (light blue arrowheads). These 
colonies also display bigger mitosis (light yellow arrows) and few cytokinesis bridges (light yellow arrowheads) than 
colonies expressing GFP-Aurora B wild-type form.  
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1.3.1 SUMOylation of Aurora B is important for correct mitotic progression and completion of 
cytokinesys 
We first validated the generated stable cell lines by selecting the total and the GFP-positive cell 
population for cell cycle profile analysis (Figure 14a). Proliferation of the clones stably expressing 
GFP-Aurora B fusion proteins is normal, although cells expressing D205A and K207R mutants 
display slightly fewer cells in a supposed G2/M stage (4N DNA content) probably due to a 
premature exit for mitosis. Importantly, GFP-Aurora B-WT expression is cell cycle regulated and 
the corresponding 5% of GFP-positive cells are mainly at a presumptive G2/M stage (4N). The 
percentage of GFP-positive cells in the mutant stable clones is slightly lower than in the case of the 
wild-type (4.3% and 3.0% of GFP-Aurora B-D205A and –K207R positive cells, respectively) and 
strikingly, expression of the mutants is not restricted to G2/M but also present in G1/S phases, 
especially in the case of D205A mutant. This altered expression of the mutants may be explained 
by a higher stability of the mutant proteins and/or by the existence of aneuploid cells in mitosis 
with a DNA content distinct than 4N.   
 To study the cellular effect of expressing a SUMO-dead Aurora B form we depleted in 
HeLa cells the endogenous human Aurora B by siRNA treatment and we let the cells grow during 
36h with exogenous siRNA-resistant mouse Aurora B-GFP fusion proteins (Figure 14b). GFP-
Aurora B-WT efficiently counteracts the formation of multinucleated cells after depletion of 
endogenous Aurora B and progress normally through mitosis, whereas expression of D205A and 
K207R mutants was unable to rescue mitosis and arrest cells at prometaphase, failing to execute 
cytokinesis and resulting in multinucleated cells. Similar results are observed after chemical 
inhibition of Aurora B kinase activity with ZM447439 (ZM1) (Figure 14c,d and pictures). A 
detailed examination of the mitotic distribution of these stable cell lines after depletion of 
endogenous Aurora B confirms that expression of GFP-Aurora B-D205A and -K207R provokes an 
arrest at prometaphase and a reduction in cells telophase (Figure 14e). This reduction in cells 
exiting mitosis is accompanied by a decrease in the percentage of cells in cytokinesis (Figure 14f). 
In addition, the remaining cells in cytokinesis are mostly aberrant and frequently display 
chromosomal bridges between the two daughter cells. 
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Figure 14. Lack of Aurora B SUMOylation disrupts mitotic progression and cytokinesis. HeLa cells stably expressing 
siRNA-resistant mouse Aurora B fused to GFP were first validated by flow cytometry, then nucleofected with human 
Aurora B siRNA oligonucleotides or a control siRNA and analyzed 36h after nucleofection by immunoblotting and 
immunofluorescence. (a) Generation and validation of HeLa stable cell lines by cytometry cell cycle analysis. The 
analysis of the total cell population is shown in blue histograms, while the analysis of the GFP-positive population is 
shown in orange histograms accompanied by the percentage of these cells over the whole population. At least three 
different stable clones were generated for each GFP-Aurora B fusion protein. Depicted histograms are from 
representative stable clones. (b) Western blot showing efficient depletion of human endogenous Aurora B and siRNA-
resistance of GFP-Aurora B proteins in HeLa stable cell lines. Tubulin was used as loading control. (c) Bar graph 
quantification of the percentage of interphase multinuclei cells. Stable expression of GFP-Aurora B-D205A and -K207R 
induces accumulation of multinucleated cells (see picture) upon depletion of endogenous Aurora B. Around 1000 
interphase cells were counted per point. (d) Bar graph quantification of the percentage of mitotic cells in prometaphase 
revealing a significant arrest at this stage caused by chromosome misalignment (see picture) in the abscence of 
endogenous Aurora B in cells stably expressing GFP-Aurora B-D205A and -K207R. At least 50 mitotic cells were 
counted per point. Chemical inhibition of Aurora B kinase activity with ZM447439 (ZM1) was included in (c) and (d) as 
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positive control. (e) Mitotic distribution of stable cell lines after depletion of endogenous Aurora B. Expression of GFP-
Aurora B-D205A and -K207R provokes an arrest at prometaphase and a reduction in cells at telophase. P: prophase, 
PM: prometaphase, M: metaphase, A: anaphase, T: telophase. (f) Bar graph quantification of interphase cells in 
cytokinesis. GFP-Aurora B-D205A and -K207R stable cell lines show a decrease percentage of cells in cytokinesis. The 
remaining cytokinesis figures are usally abnormal with chromosomal bridges (arrows). -tubulin (-tub) staining is in red, 
GFP-Aurora B in green and DAPI (DNA) in blue. 
 
1.3.2 SUMO regulates Aurora B and Incenp centromeric localization 
To further investigate the mitotic defects caused by the expression of a SUMO-dead Aurora B 
protein we performed immunofluorescence analysis of HeLa stable cell lines 36 hours after 
depletion of endogenous Aurora B. Fluorescence microscopy analysis shows that Aurora B-K207R 
mutant was distributed along the entire chromosome arms in prometaphase (PM) and metaphase 
(M) cells (Figure 15a). Interestingly, the CPC component Incenp was also dispersed on chromatin 
failing to concentrate in inner centromeres suggesting localization defects of the whole complex 
upon lack of Aurora B SUMOylation. A similar delocalization behavior, albeit less dramatic, was 
observed for the Aurora B-D205A kinase-dead mutant where additional chromosome alignment 
defects are present. In contrast, Aurora B-wild-type remained focused at the centromere region 
upon chromosome condensation, as visualized by the dotted localization pattern on PM/M 
chromosomes (Figure 15a). Quantification of the percentage of PM/M cells with delocalized 
Aurora B / Incenp signal revealed that this phenotype only appears in the absence of endogenous 
Aurora B when K207R mutant and, in a less extent, D205A are expressed (Figure 15b). Further 
analysis of Aurora B dispersion using pseudocolour images treated with metamorph software 
confirms D205A and K207R signal dispersion on chromosomes (Figure 15c and insets). 
Quantification of the integrated optical density (OD) which is used to analyze the opacity of an 
object when exposed to transmitted light, shows that the chromosomal staining of a SUMO-dead 
Aurora B form is significantly (p<0.001) less opaque than Aurora B-WT staining meaning that 
Aurora B-K207R does not concentrate at any chromosomal region (Figure 15d). 
To address whether Aurora B kinase activity is important for proper Aurora B localization 
in the centromere, we treated GFP-Aurora B-WT stable cell line with ZM1 inhibitor. Consistant 
with previous reports (Ditchfield et al., 2003), chemical inhibition of Aurora B kinase activity does 
not perturb Aurora B or Incenp localization in the centromere indicating that an active kinase is not 
required for their centromeric localization (Figure 15e). All together, our data indicate that SUMO 
modification of Aurora B is crucial to regulate Aurora B and Incenp dynamics at centromeres. 
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Figure 15. SUMOylation of Aurora B is important for AuroraB/Incenp localization in the centromere. (a) 
Immunofluorescence images of HeLa stable cell lines after depletion of endogenous Aurora B. GFP-Aurora B-D205A 
and -K207R mutants together with Incenp display a disperse localization over the chromatin in PM/M cells. Multipolar 
spindles are also present in these mutant cells (white open arrows). (b) Bar graph quantification of the percentage of 
PM/M cells in which GFP-Aurora B fusions and Incenp are delocalized. Delocalization of Aurora B is only observed in 
D205A and K207R mutants after depletion of the endogenous protein. At least 50 mitotic cells were counted per point. 
(c) Image pseudocolour treatment with metamorph software to visualize the distribution of GFP-Aurora B signal in stable 
cell lines after depletion of endogenous Aurora B. Intensity of the signal is represented in a colour scale: (low) purple, 
blue, green, yellow, red (high). (d) Bar graph quantification of the integrated optical density (OD) of GFP-Aurora B signal 
over the chromatin shows a significant reduction (p<0.0001) of GFP-Aurora B-K207R signal density. (e) Chemical 
inhibition of Aurora B with ZM1 does not mislocalize the protein although it provokes chromosome misalignment (white 
arrows). -tubulin staining is in red, Incenp in (e) is also in red, GFP-Aurora B in green and DAPI (DNA) in blue. 
1.3.3 SUMOylation affects Aurora B function without reducing its kinase activity  
Next, we asked whether a SUMO-dead Aurora B form was able to rescue the mitotic functions of 
the CPC. For this purpose we analyzed the phosphorylation status of CENP-A, a known Aurora B 
substrate, in our stable cell lines 36 hours after depletion of endogenous Aurora B. The staining 
with phospho-specific antibodies against CENP-A reveals that delocalized D205A and K207R 
mutants are unable to phosphorylate CENP-A (Figure 16a). In contrast, GFP-Aurora B-WT which 
is concentrated in the centromeres efficiently phosphorylates CENP-A resulting in positive staining  
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Figure 16. Centromeric mislocalization of Aurora B-K207R mutant prevents CENP-A phosphorylation without reducing 
its kinase activity. (a) Immunofluorescence images from HeLa stable cell lines treated with siRNA against endogenous 
Aurora B. GFP-Aurora B-D205A and -K207R accumulate along chromosome arms and fail to phosphorylate CENP-A. -
tubulin staining is in red, P-CENP-A if present is in red, GFP-Aurora B in green and DAPI (DNA) in blue. (b) In vitro 
kinase activity toward recombinant MBP of V5 tagged Aurora B proteins. HEK293 cells were transiently transfected with 
the indicated V5-Aurkb expression vectors and the resulting exogenous expressed proteins were immunoprecipitated 
with -V5 antibody. The kinase activity of a SUMO-dead (K207R) Aurora B form is not reduced but partially increased. 
Aurora B kinase-dead mutants K111M and D205A were included as negative controls of MBP phosphorylation. 
Quantification of 32P-MBP signal was calculated considering the total amount of V5-Aurora B protein in each case.   
 
for P-CENP-A at the inner kinetochores flanking GFP-Aurora B-WT signal (Figure 16a, inset). To 
determine the reason by which lack of SUMOylation perturbs Aurora B function, we tested the 
kinase activity of V5 tagged Aurora B proteins immunoprecipitated from transiently transfected 
HEK293 cells (Figure 16b). Consistant with structural predictions, K111M and D205A mutants fail 
to efficiently phosphorylate MBP substrate in vitro, although K111M still present some kinase 
activity. Strikingly, the kinase activity of Aurora B-K207R mutant is not reduced but increased if 
compared with Aurora B wild-type activity. Therefore, these data support the idea that lack of 
SUMOylation perturbs Aurora B function by impeding its proper localization in centromeres and 
not by reducing its kinase activity. 
1.3.4 An abnormal SUMOylation of Aurora B affects its oncogenic properties  
It has been reported that elevated Aurora B activity promotes cellular transformation in vitro by 
enhancing oncogenic Ras signaling (Kanda et al., 2005). To test the oncogenic properties of a 
SUMO-dead Aurora B form, we performed focus formation assays in NIH-3T3 cells, a well known 
cell line susceptible to transformation with various oncogenes (Clark et al., 1995).We stably 
transfected NIH-3T3 cells with V5-Aurora B expression vectors in combination or not with 
oncogenic HRas-G12V expression vector and examined its effect on the frequency of cellular foci 
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resulted from HRas-G12V-induced transformation (Figure 17). As previously reported, although 
Aurora B wild-type expression alone is not able to promote malignant cell transformation it 
significantly augments the frequency of HRas-G12V transformation. Importantly, this potentiation 
was suppressed by cotransfection with Aurora B-D205A kinase-dead vector, confirming that 
Aurora B kinase activity promotes cell transformation in combination with HRas (Kanda et al., 
2005). On the contrary, cooperation with HRas is significantly increased (p<0.05) upon expression 
of Aurora B-K207R, suggesting that lack of SUMOylation facilates cell transformation. Finally, to 
address if genetic instability contributes to the formation of a transformed phenotype, we counted 
the number of chromosomes of the resulted foci. In all cases, the analyzed cells displayed a similar 
number of chromosomes suggesting that chromosomal instability is not supporting HRas 
oncogenic activity. 
 
 
Figure 17. An abnormal SUMOylation of Aurora B affects its oncogenic properties. (a) Focus formation assay in NIH-3T3 
cells. Depiction of transformed foci in Giemsa-stained dishes in NIH-3T3 cells cotransfected with HRasG12V and V5-
Aurkb expression vectors. An empty V5-vector was used as control. (b) Bar graph quantification of the number of 
transformed foci. Expression of SUMO-dead Aurora B significantly increases (p>0.05) the number of HRas-induced foci 
when compared with Aurora B-WILD-TYPE counterpart. (c) Chromosome quantification of transformed and normal 3T3 
cells. Lack of SUMOylation of Aurora B does not induce genetic instability in 3T3 cells.  
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2. Development of mouse models 
Aurora B function has been extensively studied in yeasts, nematodes, insects and cold-blood 
vertebrates but very limited information concerning Aurora B role in mammals and in its 
implication in tumorigenesis is available. To study the in vivo function of Aurora B in mammals 
we have generated three different mouse models: a conditional knock-out model (Figure 18), a 
knock-in model (Figure 19) and a tetracycline inducible model (Figure 20 and 21).  
2.1 Generation of a conditional knock out mouse model 
To generate a conditional knock-out model we first constructed a targeting vector in which Aurora 
B exons 2-6 are flanked with loxP sequences and a frt-neo
r
 (neomycin-resistant gene)-frt cassette 
for selection purposes (Figure 18). At both ends of the construct we cloned two homology arms to 
facilitate homologous recombination in ES cells. After homologous recombination, we selected 
clones carrying the recombinant alleles Aurkb(loxfrt) (Figure 18b) and the corresponding ES cells 
were microinjected into wild-type blastocysts to generate Aurkb(+/loxfrt) mice. The neo
r
 cassette 
was first removed by crossing with transgenic mice expressing the Flp recombinase (see Methods) 
resulting in the conditional Aurkb(lox) allele. Germline deletion of exons was achieved by 
additional crosses with CMV-Cre transgenic mice to generate the Aurkb(–). Note that elimination 
of exons 2-6 in Aurkb(–) allele ensures total inactivation of Aurora B gene since we are removing 
almost completely the kinase domain of Aurora B protein. Moreover, in case of alternative splicing 
between exon 1 and 7 the codified protein is not going to be related with Aurora B since there is a 
change in the reading frame between these exons. Genotyping of these alleles was done by PCR 
using DNA extracted from the tails of these mice and two distinct combination of primers (1+3 and 
2+3, Figure 18a,c). 
2.2 Generation of a -Galactosidase knock-in mouse model  
In addition, we followed the FLEx strategy (Schnutgen et al., 2003) to generate a knock-in allele, 
Aurkb(Z), in which expression of the endogenous Aurkb gene is replaced by lacZ transcripts 
encoding -galactosidase. A detailed description of the strategy followed is shown in Figure 19a. 
To confirm activity of Aurora B promoter by the -galactosidase reporter we performed X-Gal 
staining of Aurkb(+/Zloxfrt) and Aurkb(+/Z) ES cells (Figure 19d). Both the Aurkb(–) and 
Aurkb(Z) alleles are null for Aurora B expression, as detected by immunofluorescence (see below), 
and lead to similar phenotypes. 
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Figure 18. Generation of conditional and null Aurora B alleles. (a) Schematic representation of the Aurkb knock-out 
alleles. The mouse Aurkb locus encoding Aurora B contains 8 exons (boxes) containing noncoding (open boxes) or 
protein-coding (filled boxes) sequences. Wild-type (white triangles) loxP sites and frt (black triangles) sites are used to 
flank Aurora B exons or the neo-resistance in the targeting vector. This neo cassette (black) contains promoter and poly-
A sequences and it is used for selection of clones after homologous recombination (HR) in ES cells. The neo cassette is 
eliminated in vivo by crossing Aurkb(+/loxfrt) mice with transgenic mice expressing the Flp recombinase. Further excision 
of exons 2-6 is mediated by expression of the Cre recombinase resulting in the Aurkb(–) null allele. Also shown are the 
ScaI restriction sites, 5’ and neo probes and primers 1, 2 and 3 used for genotyping. (b) Southern blot analysis of 
recombinant ES cells showing two Aurkb(+/loxfrt) clones that underwent HR. DNA was digested with ScaI and hybridized 
with the probe 5’ or neo specific sequences (c) PCR genotyping of tail DNA using primers 1, 2 and 3, confirming the 
presence of Aurkb(lox) and Aurkb(–) alleles. 
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Figure 19. Generation of knock-in mice in which Aurora B expression has been replaced by -Galactosidase . (a) 
Schematic representation of the Aurkb knock-in alleles generated following FLEx strategy (Schnutgen et al., 2003). 
Aurora B exons 2-4 were flanked with wild-type and mutant loxP sequences following the FLEx strategy. An internal 
ribosome binding site (IRES)-lacZ cassette is placed in the opposite orientation between exons 4 and 5. This cassette 
contains the splicing acceptor of Aurkb exon 2 (lined box) upstream of the IRES sequence and the SV40 polyA sequence 
(not indicated) downstream of the lacZ gene. The corresponding targeting vector was electroporated into ES cells. After 
homologous recombination in ES cells, we selected clones carrying the recombinant allele Aurkb(Zloxfrt) and the 
corresponding ES cells were aggregated to generate Aurkb(+/Zloxfrt) mice. The neomycin-resistant cassette was first 
removed by crossing with transgenic mice expressing the Flp recombinase. This results in the Aurkb(Zlox) allele carrying 
an inverted IRES-lacZ cassette. After expression of Cre recombinase, this cassette is inverted due to the presence of 
opposite loxP or lox511 mutant sites as described previously (Schnutgen et al., 2003). The resulting Aurkb(Z) allele 
expresses the lacZ gene downstream of the Aurkb exon 1 resulting in a truncated Aurora B transcript and the 
concomitant expression of -galactosidase. (b) Southern blot analysis of ES cell clones after homologous recombination 
indicating the presence of the recombinant allele Aurkb(+/Zloxfrt) in some of these clones. The situation of the probes 5’ 
and 3’ is indicated in (a). (c) Representative genotyping of the Aurkb(+), Aurkb(Zlox) and Aurkb(Z) alleles corresponding 
to (a). The position of oligonucleotides (Z1 and Z2) used for PCR genotyping is represented in panel (a). (d) Expression 
of -galactosidase from the Aurkb(Z) but not Aurkb(Zloxfrt) alleles. Aurkb(+/Zloxfrt) ES cells were infected with a vector 
expressing the Cre recombinase to generate Aurkb(+/Z) cells. Both infected and non-infected cells were stained for -
galactosidase activity (blue colour). 
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2.3 Generation of a tetracycline-inducible mouse model 
Finally, in collaboration with Professor Earnshaw‟s laboratory at the Wellcome Trust Centre for 
Cell Biology in Edinburgh we generated an inducible mouse model in which Aurora B gene 
expression can be potentially modulated by the addition of tetracycline (Figure 20 and 21). This 
approach centers on a „promoter-hijack‟ strategy first described by Earnshaw‟s laboratory for DT40 
cells (Samejima et al., 2008) in which the gene‟s promoter is replaced with a minimal 
cytomegalovirus (CMV) promoter upstream-linked with seven in-tandem repeats of tetO 
sequences. This construction leads to a Tet-responsive minimal promoter (Tet-P) that is only active 
in the presence of binding of the transactivator regulatory proteins (tTA or rtTA) to the tetO 
sequences. We also generated a targeting vector to modify the remaining Aurora B allele in order 
to drive expression of a tTA from the Aurora B endogenous promoter (Figure 21b). Thus, in a 
mouse harboring both modified alleles, Aurkb(tet/tTA), Aurora B gene will be essentially regulated 
by its own promoter but through the intermediary tTA. Alternatively, we crossed Aurkb(+/tet) mice 
with knock-in mice expressing an M2rtTA under the ubiquitious Rosa26 promotor (Beard et al., 
2006) (Figure 21b). In this other case, Aurkb(+/tet);Rosa26(+/rtTA) mice will be used to induce 
Aurora B ubiquitous expression in vivo in a conditional way. Modulation of this system is achieved 
by addition of tetracycline as depicted in Figure 21c.  
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Figure 20. Generation of inducible mice in which Aurora B promoter has been replaced by a tetracycline-responsive 
minimal promoter. (a) Schematic representation of the alleles generated in the inducible mouse model. Aurora B 
endogenous promoter was replaced by tet-P which is a minimal CMV promoter that contains seven in-tandem repeats of 
tetO sequences recognized by the transactivator regulatory proteins tTA and rtTA. The corresponding targeting vector 
was electroporated into ES cells. After homologous recombination in ES cells, we selected clones carrying the 
recombinant allele Aurkb(lox-tet) by positive and negative selection using puromycin and thymidine kinase resistance 
genes, respectively. The corresponding ES cells were aggregated to generate Aurkb(+/lox-tet) mice. The puromycin-
resistant cassette was then removed in vivo by crossing with transgenic mice expressing the Cre recombinase. This 
results in the Aurkb(tet) that contains a minimal tetO-CMV promoter (Tet-P) instead of Aurora B endogenous promoter. 
(b) Southern blot analysis of ES cell clones after homologous recombination indicating the presence of the recombinant 
allele Aurkb(+/lox-tet) in one of the clones. The situation of the probes 5’ and 3’ is indicated in (a). (c) Representative 
genotyping of the Aurkb(+) and Aurkb(tet). The position of oligonucleotides (tet1, tet2 and tet3) used for PCR genotyping 
is represented in panel (a). 
 
Results 
 
49 
 
 
 
 
Figure 21. Promoter-hijack approach for inducible expression of Aurora B. (a) The Aurkb(tet) allele contains a minimal 
tetO-CMV promoter (Tet-P) instead of Aurora B endogenous promoter. This cassette contains seven in-tandem repeats 
of tetO sequences recognized by transactivator regulatory proteins (tTA and rtTA). In the absence of binding of these 
regulatory proteins to tetP Aurora B gene is silenced. White triangle is a remaining loxP site after the targeting strategy 
(see Figure 12a). (b) Recombinant alleles expressing transactivator regulatory proteins under different promoters. The 
Aurkb(tTA) allele contains a tTA cassette (green) instead of Aurora B codifying exons 1-4. The tTA cassette contains a 
fusion sequence of the tet repressor and the activation domain of VP16 protein, as well as poly-A sequences for 
termination of transcription. Expression of this cassette is driven by Aurora B regulatory sequences. The Rosa26(rtTA) 
allele generated in (Beard et al., 2006) expresses a tetracycline-inducible M2rtTA transactivator driven from the 
endogenous ubiquitous Rosa26 promoter. (c) Addition of tetracycline modifies the configuration and binding of tTA and 
rtTA to the tetO sequences. rtTA binds to and activates expression of tet-P in the presence of tetracycline (Tet-ON 
system); whereas, tTA only binds to tet-P in the absence of tetracycline (Tet-OFF system). 
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3. Partial in vivo inactivation of Aurora B 
3.1 Lack of one allele of Aurora B does not result in major alterations during mouse 
development 
After generation of the mice colony we observed that Aurora B heterozygous null mice are healthy 
during adult life suggesting that mice can develop normally with reduced allele dosage of Aurora 
B. 
3.1.1 Aurora B heterozygous MEFs proliferate well in culture 
To further confirm that Aurora B heterozigosity does not lead to defects in cell cycle progression 
we extracted Aurkb(+/+) and Aurkb(+/–) mouse embryonic fibroblasts (MEFs) from embryos at 
E14.5 (Methods) and we analysed the cell cycle profile of asynchronic cultures of these primary 
cells. Similarly to Aurkb(+/+) control MEFs, Aurkb(+/–) MEFs proliferate well in culture and do 
not display obvious defects during cell cycle progression (Figure 22). 
3.1.2 Aurora B heterozygous mice are fertile although few of them develop hypospermia  
To check if heterozygous mice were fertile, we crossed Aurkb(+/–) mice and we observed that 
heterozygous males and females were able to reproduce normally. However, few Aurkb(+/–) males 
(16,6% incidence) develop hypospermia by 12 months of age, in agreement with a relevant role of 
Aurora B during spermatogenesis (Figure 23) as suggested previously (Kimmins et al., 2007). To 
further explore this phenotype we analysed testis sections from Aurkb(+/+) mice (n=4) and 
 
 
Figure 22. Normal cell proliferation in Aurkb(+/–) embryonic fibroblasts. DNA content profile of primary (passage 2) 
asynchronous Aurkb+/+ and Aurkb+/– MEFs in complete medium with 10% FBS. Percentage of cells in each phase of 
the cell cycle is shown at the right panel. 
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Figure 23. Hypospermia in Aurkb(+/–) males. (a) Immunohistochemical analysis of phosphorylated Ser10 of histone H3 
(P-H3) in epididymis sections revealing absence of spermatozoa in Aurkb(+/–) male. (b) Hematoxylin/eosin-stained 
testes sections showing aberrant tubule morphology in Aurkb(+/–) male. Bar graph quantitating the percentage of 
abnormal tubules per mouse at 12 months of age (down left panel), and detail of a tubule from a Aurkb(+/–) male with 
two multinucleated aberrant cells (down, right panel). 
 
Aurkb(+/–) mice (n=6) by 12 months and we found a significant increase in defective tubules in 
Aurkb(+/–) that correlates with empty seminiferous tubules in the epididymis (Figure 23). 
Interestingly, few multinucleated cells were only present in Aurkb(+/–) tubules suggesting 
spermatogenesis defects specifically in mice with reduced levels of Aurora B.  
3.2 Lack of one allele of Aurora B results in impaired proliferation and slight protection 
against tumour induction 
Aurora B is an essential regulator of cell division in yeasts, nematodes, insects, cold-blood 
vertebrates and in most of the cell lines tested (Ruchaud et al., 2007). In mammals, Aurora B is 
expressed in the majority of the proliferative tissues (Terada, 1998). However, the requirement of 
Aurora B for in vivo proliferation in mammals is not known.  
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3.2.1 Impaired in vivo proliferation in Aurkb(+/–) mice 
To investigate if the lack of one Aurora B allele may result in specific proliferative alterations in 
vivo, we first performed wound healing assays in the skin of Aurkb(+/+) and Aurkb(+/–) mice. As 
depicted in Figure 24a, Aurkb(+/–) mice display a delay in wound closure in the skin. Whereas 
wild-type animals take about 2.5 days to heal 50% of the wound area, Aurkb(+/–) mice require one 
additional day (40% more time). This delay correlates with a decrease in proliferation in skin 
keratinocytes as measured by Ki67 immunodetection in these samples (Figure 24b) indicating that 
complete protein levels of Aurora B are required for skin proliferation when animals are submitted 
to challenging proliferative conditions.  
3.2.2 Slight protection against tumour induction in Aurkb(+/–) mice 
To analyse whether the impaired proliferation observed in the skin of Aurkb(+/–) has any relevance 
in cancer progression, we submitted Aurkb(+/–) mice to two different routine carcinogenic 
 
Figure 24. Delayed closure of biopsy wounds in Aurkb(+/–) mice. (a) Images showing 4mm-wounds closing 2, 3, 4 and 5 
days after biopsy in Aurkb(+/+) and Aurkb(+/–) 12 months-old mice. Line graph plotting the rate of wound closing 
showing that Aurkb(+/–) mice needs more time to close the wound than Aurkb(+/+) mice. (b) Immunohistochemical 
analysis of ki67 proliferation marker in skin sections close and distant (approximately 150mm away) to the wound (large 
and short scale bar: 100 and 10m, respectively). Bar graph quantification of ki67 positive keratinocytes showing 
significantly less proliferation in distant areas to the wound in Aurkb(+/–) mice. 
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treatments, 3-MC and the two-stage carcinogenesis protocol using DMBA and TPA (Methods). As 
indicated in Figure 25a, lack of one allele of Aurora B results in a slight, although not significant, 
protection against 3-MC-induced fibrosarcomas. Similar results are obtained using the 
DMBA+TPA protocol (Figure 25b). Thus, the incidence of DMBA-TPA-induced papillomas in 
Aurkb(+/–) mice is reduced, in comparison with control mice, by one unit during the first three 
weeks of the treatment and from week 12 to week 15. Finally, we also induced tumours in the 
mammary gland in Aurkb(+/–) females by crossing these animals with transgenic mice expressing 
the Erbb2 oncogene under the mouse mammary tumour virus (MMTV) promoter sequences. As in 
the previous assays, lack of one allele of Aurora B did not significantly modify the survival of these 
transgenic mice although Aurkb(+/–) mice tend to survive longer as in the case of 3-MC induced 
tumours (Figure 25c). We conclude that lack of one allele of Aurora B has a minor protective effect 
against tumour induction. 
 
Figure 25. Minor protective effect against tumor induction in Aurkb(+/–) mice. (a) Incidence of 3MC-induced 
fibrosarcomas in mice (see Materials and methods). The time of appearance of tumors (>1.5 cm diameter) was scored 
for each genotype Aurkb(+/+) n=16 and Aurkb(+/–) n=13. (b) Incidence and latency of DMBA-TPA induced papillomas in 
mice (see Materials and methods). Papillomas’s size is represented using a coloured scale (grey for < 3mm, blue for 3-
6mm, yellow for 6-9mm and red for > 9mm) for each genotype Aurkb(+/+) n=13 and Aurkb(+/–) n=10 (c) Incidence of 
Erbb2 genetically-induced mammary tumors in female mice. Erbb2 oncogene is expressed under the mouse mammary 
tumour virus (MMTV). The time of appearance of tumors (>1.5 cm diameter) was scored for each genotype Aurkb(+/+) 
n= 9 and Aurkb(+/–) n=22. 
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3.3 Lack of one allele for Aurora B increases susceptibility to spontaneous tumour 
development in aged mice  
Although Aurkb(+/–) mice do not show gross abnormalities during adult life, we observed that 
these heterozygous mutant mice display a decreased survival at later ages (Figure 26a). Thus, 
whereas 83,3% of Aurkb(+/+) mice are alive by 26-months of age, only 11,8% of Aurkb(+/–) 
survive by this age. Indeed, the half-life span of these mutant mice is reduced by 6 months 
compared to their wild-type littermates (half-life of 24.2 months in mutant mice versus 30.5 months 
in wild-type mice). This lethality is accompanied by a significant increase in the percentage of 
heterozygous mice with spontaneous tumours by 24 months of age (Figure 26b). In particular, these 
mutant mice display a tumour spectrum (mainly pituitary, liver adeno/carcinomas and skin 
papillomas) that is not observed in the control group (Table 7). In addition, about 33% of 
Aurkb(+/–) mice develop B-cell lymphomas, a type of tumour that it is commonly observed in 
wild-type mice. These data indicate that Aurkb(+/–) mice display a significant tumour susceptibility 
with age. 
Table 7. Tumours observed in aged Aurkb mutant mice 
 Aurkb(+/+) Aurkb(+/–) 
Tumours Incidence 
(%) 
Latency 
(months) 
Incidence 
(%) 
Latency 
(months) 
     
B-cell Lymphoma  
Lung Adenoma  
66.6 (4/6) 
16.6 (1/6) 
29 
26 
33.3 (3/9) 
22.2 (2/9) 
23 
21 
Pituitary Adenoma 
Papilloma 
Liver Adeno/carcinoma 
Thymic angioma 
0 
0 
0 
0 
- 
- 
- 
- 
22.2 (2/9) 
22.2 (2/9) 
22.2 (2/9) 
11.1 (1/9) 
22 
18 
28 
22 
Hemangioma 
Sarcoma  
16.6 (1/6) 
16.6 (1/6) 
30 
26 
0 
0 
- 
- 
Bile duct adenoma 16.6 (1/6) 26 0 - 
 
 
Figure 26. Increased susceptibility to tumour 
development in aged Aurkb(+/–) mice. (a) Survival 
curve of Aurkb(+/+) and Aurkb(+/–) mice indicating a 
slight but significant reduction in the life span of 
these mutant mice. (b) Bar graph quantification of 
percentage of mice with tumours at 24 months of 
age revealing a significant increase in tumour 
appearance in Aurkb(+/–) mice. (c) Representative 
pathology of the tumours observed in Aurkb(+/–) 
mice. Images of pituitary and liver carcinomas and 
skin papillomas  
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4. Lethality and complementation by Aurora C 
4.1 Genetic ablation of Aurora B does not disturb early embryonic divisions 
4.1.1 Aurora B-deficient embryos progress normally to a blastocyst stage  
To generate homozygous mutants, we intercross Aurkb(+/–) or Aurkb(+/Z) mice and analyzed their 
progeny. No homozygous mutant mice were observed from any of these crosses suggesting 
embryonic lethality (Table 8). Similarly, no homozygous embryos are observed at mid gestation 
(E10.5-E14.5) indicating that Aurora B is required for completing embryonic development. Since 
genetic ablation of the other CPC components, Incenp, Survivin or Borealin prevents embryonic 
cell divisions as early as E2.5 (Cutts et al., 1999; Uren et al., 2000; Yamanaka et al., 2008), we 
decided to isolate fertilized embryos at E2 (Methods). By this stage most embryos are at the 4-cell 
stage (Figure 27a). After four additional days in culture, wild-type and heterozygous embryos form 
normal morulas and blastocysts. Unexpectedly, the mendelian ratio of Aurkb(–/–) embryos (27 out 
of 121 embryos, Table 8) also form normal blastocysts by E5.5 without any evident sign of 
decreased size or cellular death (Figure 18a). Same results are observed in Aurkb(Z/Z) embryos 
which are able to form blastocysts similar to their wild-type littermates (Figure 27b).  
4.1.2 Aurora B is expressed during first cell divisions 
 To test whether Aurora B is expressed at these early developmental stages, we took advantage of 
the -galactosidase reporter expressed in the Aurkb(Z) allele. As shown in Figure 27b, we detected 
positive staining for -galactosidase suggesting that the Aurkb regulatory sequences are active in 
these early embryonic cycles. Expression of Aurora B was also confirmed at different early 
developmental stages by immunofluorescence. As depicted in Figure 28, Aurora B is detected at 
 
Figure 27. Normal development of pre-implantation embryos lacking Aurora B. (a) E2 embryos were isolated from 
intercrosses between Aurkb(+/–) mice and cultured for 4 additional days. These embryos were genotyped by PCR 
analysis at E5.5. (b) Analysis of -galactosidase expression in Aurkb(+/+) and Aurkb(Z/Z) embryos by E5.5 showing lacZ 
expression from the endogenous Aurkb promoter sequences.  
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the expected cellular structures (centromeres, midbody and cytokinesis bridges) in early wild-type 
embryos at all stages tested. Aurora B, however, is not detected in fertilized Aurkb(–/–) embryos as 
early as the 2-cell stage or later developmental phases (see below). Thus, the lack of defects in 
Aurkb(–/–) morulas or blastocysts is not a consequence of uncontrolled expression of Aurora B or 
maternal contribution but rather an indication of dispensability of Aurora B in the cell division 
cycle, at least during these stages. 
Table 8. Analysis of mice and embryos obtained from Aurkb(+/–) intercrosses 
Genotypes of live births and embryos 
Age Aurkb(+/+) Aurkb(+/–) Aurkb(–/–) Reabsorbed Total 
Newborns 48 (33.8%) 94 (66.2%) 0 0 142 
E10.5 - E14.5  16 (29.1%) 31 (56.4%) 0 8 (14.5%) 55 
      
Embryos grown in culture 
Stage Aurkb(+/+) Aurkb(+/–) Aurkb(–/–)  Total 
Blastocysts E5.5 39 (32.2%) 55 (45.5%) 27 (22.3%)  121 
Healthy at E8.5 7 9 0  16 
ICM atrophied 1 1 7  9 
      
Histological analysis of embryos in utero 
Stage  Aurkb (+) Aurkb (-) Empty Total 
E9.5  18 (72.0%) 4 (16.0%) 3 (12.0%) 25 
E7.5  13 (68.4%) 5 (26.3%) 3 (5.3%) 19 
 
 
Figure 28. Aurora B is expressed during early embryonic development. Immunofluorescence images of oocytes and 2-3 
cell embryos stained for -tubulin (red), Aurora B (Aurkb, in green) and DAPI (DNA, in blue). Aurora B localizes to the 
chromosomes during prometaphase and to the midbody in cytokinesis. No staining is observed in Aurora B-deficient 
embryos despite the normal mitotic figures observed. Scale bars, 20 m. 
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4.1.3 Histone H3 is properly phosphorylated and Incenp is correctly localized in early embryos 
lacking Aurora B 
Aurora B as part of the CPC phosphorylates Histone H3 at Ser10 to facilitate chromosome 
condensation at the beginning of mitosis. To study Aurora B activity in early embryos we used a 
phospho-specific antibody against histone H3-S10. Intriguingly, Aurora B-null morulas display 
normal mitosis with phosphorylated histone H3 (P-H3), indicating normal chromosome 
condensation (Figure 29a) in the absence of Aurora B.  
As it has been described that the CPC members are physically and functionally 
interdependent and that disruption of any member of the complex delocalizes the others (Gassmann 
et al., 2004; Jeyaprakash et al., 2007) we decided to analyse the stability of the CPC in the absence 
of Aurora B by checking Incenp localization. Interestingly, Aurora B-null embryos display the 
expected localization of Incenp, which co-localizes with Aurora B in wild-type cells but it is also 
properly located despite the lack of Aurora B (Figure 29b). These results suggest that Aurora B 
typical functions are carried out normally in early mutant embryos.  
 
Figure 29. Normal phosphorylation of Histone H3 and localization of the CPC component Incenp in Aurora B-null pre-
implantation embryos. Immunofluorescence images of embryos extracted at E1.5 and E2.5 days. (a) Expression of 
Aurora B (Aurkb in green) indicating its colocalization with phospho-histone H3 (P-H3 in pink) in mitotic cells of E2.5 pre-
implantation embryos. In the absence of Aurora B, mitotic cells are also present in the same frequency and display 
normal staining for P-H3. (b) Incenp (green) is also properly localized (arrows) in early embryos in the presence or 
absence of Aurora-B. -tubulin staining is shown in red and DAPI (DNA) in blue. Scale bars, 20 m. 
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4.1.4 Aurora B-null blastocysts display normal size and cell number 
To explore at the cellular level if Aurora B is also dispensable to form a functional blastocyst, we 
performed immunofluorescence studies in normal and in Aurora B-deficient embryos at E4.5. As 
expected from the previous result (Figure 27), Aurora B-null blastocysts display similar size and 
cell number than normal blastocysts with the typical localization of Aurora B in wild-type but not 
in mutant embryos (Figure 30).  
4.2. Genetic ablation of Aurora B results in mitotic aberrations and lethality after 
implantation  
Since Aurora B-null blastocysts develop normally, we next asked whether Aurora B is required for 
the implantation of embryos in vivo. As indicated in Table 2, we identified 26.3% of Aurora B-
negative implanted embryos by E7.5, as assayed by immunohistochemistry for Aurora B, and a 
more limited number of Aurora B-negative embryos (16%) by E9.5. All these Aurora B-deficient 
embryos display a smaller size and several histological abnormalities (see below) that prevented 
proper identification by PCR. In addition, the embryonic structures were absent in a percentage of 
deciduas (5.3% and 12% of empty deciduas at E7.5 and E9.5, respectively) suggesting additional 
dead embryos after implantation (Table 8). 
 
 
Figure 30. Aurora B-null blastocysts do not show cellular defects. Immunofluorescence images of wild-type and Aurora 
B-null blastocysts at E4.5 showing similar structure and size including normal PM and M (yellow arrows) and cytokinesis 
bridges (white arrows) despite the absence of Aurora B. Aurora B (Aurkb) staining is shown in green, -tubulin in red 
and DAPI (DNA) in blue. Alternatively, we used ACA, anti-centromeric antigen antibody shown in green. Scale bars, 20 
m.  
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4.2.1 Histological examination of abnormal implanted Aurora B-null embryos 
Histological examination by hematoxilin and eosin (H&E) staining of E7.5 embryos revealed 
defective embryos with hemorrhagia in the ectoplacental cone and frequent oedemas and apoptotic 
cells (Figure 31). Whereas there is a clear amniotic cavity in wild-type embryos by this stage, 
Aurora B-deficient embryos accumulate apoptotic cells in a small, atrophic lumen. A significant 
increase in mitotic (15.8% in Aurora B-null embryos vs. 4.4% in wild-type embryos; p < 0.001) 
and apoptotic (14.6% in Aurora B-null embryos vs. 0% in wild-type embryos; p < 0.001) cells is 
found in Aurora B-deficient embryos (Figure 31). 
4.2.2 DNA damage and activation of the p53 pathway leads to apoptosis in implanted embryos 
lacking Aurora B  
To determine which mechanisms are related with the apoptosis observed in Aurora B-deficient ES 
cells by E7.5, we analysed possible DNA damage or activation of p53 pathway in these cells. After 
immunohistochemistry detection, we observed that many of the mutant ES cells display a 
significant positive staining for H2AX (8.7% in Aurora B-null embryos vs. 0.7% in wild-type 
embryos; p < 0.001) or p53 (2.0% in Aurora B-null embryos vs. 32.9% in wild-type embryos; p < 
0.001) suggesting DNA damage and activation of the p53 pathway in these apoptotic cells (Figure 
32). Finally, to confirm that the apoptotic pathway is activated in Aurora B-deficient cells we 
examined the activated form of caspase 3 (C3A). In accordance to the presence of apoptotic cells 
observed in the H&E staining, there is a significant increase in positive C3A cells (14.9% in Aurora 
B-null embryos vs. 0.8% in wild-type embryos; p < 0.001) (Figure 32). 
 
Figure 31. Abnormal embryonic development of Aurora B-null embryos by E7.5. (a) Hematoxylin/eosin-stained uterine 
decidua sections at E7.5 showing Aurkb(+/+) or (+/–) and Aurkb(–/–) implanted embryos. Aurora B-null embryos display 
a defective ectoplacental cone (a’) with aberrant trophoblasts (arrows) and hemorrhagia. Furthermore, the amniotic 
cavities are atrophic in Aurora B-null embryos (a”) and accumulate apoptotic cells (arrows). The implanted embryo is 
surrounded by a big oedema (*). (b) Bar graph showing the significant increase of mitotic and apoptotic cells in Aurkb(–/–
) implanted embryos ( p < 0.001 in all cases). Scale bars, 100 m 
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Figure 32. Activation of p53 pathway in the presence of DNA damage leads to apoptosis in Aurora B-null embryos by 
E7.5. (a) Immunohistochemical analysis of H2AX, p53 and C3A in uterine decidua sections at E7.5 showing minimal 
staining of these markers in Aurkb(+/+) or (+/–) embryos and positive staining (arrows) of the three markers in Aurkb(–/–) 
implanted embryos. (b) Bar graph showing the significant increase in H2AX, p53 and C3A positive cells in Aurkb(–/–) 
implanted embryos ( p < 0.001 in all cases). Scale bars, 100 m 
4.2.3 Aurora B-deficient cells arrest at prometaphase/metaphase with an active SAC 
Aurora B is clearly detected by immunostaining in mitotic and other (possibly G2) cells in wild-
type embryos (Figure 33). This clear staining in wild-type embryos lead us to easily identify the 
Aurora B-null embryos as they show completely negative staining in all the embryonic structures. 
Interestingly, most of the mitotic figures observed in the Aurora B negative embryos represent cells 
in prometaphase (PM) or metaphase (M), including a significant proportion of abnormal PM/M 
figures with misaligned chromosomas (Figure 33). In addition, all these cells display a positive 
signal for Cyclin B1, suggesting that Aurora B-null cells do not progress to anaphase and arrest at a 
stage where the Anaphase-promoting complex (APC/C) is inactive probably due to a functional 
Spindle Assembly Checkpoint (SAC). 
4.2.4 Embryos fully degenerate at E9.5 in the absence of Aurora B  
By E9.5, wild-type embryos are at the beginning of mid-gestion and many of the future adult 
structures can already be distinguished (Figure 34a). On the contrary, most Aurora B-null embryos 
are degenerated at this stage with only few cells left that are mostly arrested in M/PM or apoptotic 
(Figure 34ab). This massive cellular death observed in the mutant embryos is also accompanied 
with a significant increase in aberrant multinucleated giant trophoblast cells (Figure 34c-e) 
suggesting defects in the endoreplicative cycles of these particular cells of the placenta. 
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Figure 33. Aurora B negative cells arrest at PM/M with accumulation of Cyclin B1 in E7.5 implanted embryos. (a) 
Immunohistochemical analysis of Aurora B and Cyclin B1 in uterine decidua sections at E7.5. Aurora B is readily 
detectable in mitotic figures (arrows) of Aurkb(+/+) or (+/–) cells but not in Aurkb(–/–) cells. Abnormal mitotic figures are 
frequently observed in Aurora B-null embryos (arrowhead). In wild-type cells, Cyclin B1 is present in prometaphase 
figures (arrow) but not in advanced metaphase or anaphase stages (arrowheads). Normal (arrows) or abnormal 
(arrowhead) mitotic figures in Aurkb(–/–) embryos display a positive staining for Cyclin B1 in agreement with an arrest in 
prometaphase. (b) Bar graph quantification of the distribution of mitotic cells in the different phases of mitosis indicating 
an arrest in prometaphases (PM) or metaphases (M) in Aurkb(–/–) embryos. Note that due to the low resolution of these 
paraffin sections where individual chromosomes are not detectable, many M may actually correspond to PM and 
prophases were difficult to distinguish. PM: prometaphase, M: metaphase, A: anaphase, T: telophase, Abn: abnormal. 
Scale bars, 20m 
4.3 Genetic ablation of Aurora B results in abnormal advanced blastocysts 
To gain an insight of the cellular defects caused by the lack of Aurora B we mimicked the 
implantation process using an in vitro approach called embryo “hatching” (Methods). This 
approach consists on growing blastocysts in culture for 2 to 5 days until they hatch from the zona 
pellucida and attach to the plate, and is ideal to study at the cellular level the functionality of ES 
and TGC cells 
4.3.1 Aurora B-null advanced blastocysts display an aberrant ICM surrounded with abnormal 
TGC 
To test the possible defects that Aurora B-null blastocysts may present after “hatching”, we carried 
out immunofluorescence analysis at different points. After four days in culture, wild-type 
blastocysts hatched from the zona pellucida, attached to the culture dish and generated a normal 
proliferative (as indicated by P-H3) inner cell mass surrounded by trophoblast giant cells (Figure 
35a and Methods). Aurora B-deficient embryos, on the other hand, at this stage (E9.5) displayed a 
deficient and apoptotic inner cell mass (Figure 35a) surrounded with aberrant trophoblasts with 
significant morphological alterations (Figure 35b).  
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Figure 34. Aurora B-null embryos degenerate completely at E9.5 with aberrant TGC. (a) Whole embryos extracted at 
E9.5 from Aurkb(+/–) intercrosses showing atrophic structure of   Aurora B-null embryos. (b) Hematoxylin/eosin and 
Aurora B immune staining of Aurkb(–/–) embryos revealing that the few cells remaining in the embryo are either 
apoptotic (arrowheads) or arrested in a prometaphase-like state (arrows). (c) Hematoxylin/eosin stained sections of 
placentas from E9.5 embryos showing aberrant polyploidy TGC. (d) Bar graph quantification of percentage of 
multinucleated TGC in Aurkb(+/+) n=2 and Aurkb(–/–) n=2. (e) Scatter dot-plot quantification of DNA content of TGC in  
Aurkb(+/+) n=2 and Aurkb(–/–) n=2. 
4.3.2 Lack of Aurora B prevents proper chromosome segregation in ES cells  
To analyse in detail the causes that lead to a deficient ICM in the lack of Aurora B we examined 
these ES cells at earlier stages. By E7.5, we detected numerous cells in PM or M in Aurora B-null 
embryos that were less frequently observed in control cultures. As a consequence of this arrest in 
PM/M we hardly observed cells exiting mitosis in Aurora B-deficient embryos in contrast to 
control embryos were we observed Aurora B positive cells in metaphase and cytokinesis (Figure  
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Figure 35. In vitro culture of blastocysts leads to degeneration of Aurora B-null embryos at E9.5. Phase-contrast and 
immunofuorescence images of embryos harvested at E2.5 and cultured in vitro for 7 days. (a) Aurkb(+/+) embryos form a 
robust and proliferative (as indicated with P-H3) inner cell mass (ICM) upon a layer of trophoblasts giant cells (TGC); 
whereas, Aurora B-null embryos only present few apoptotic cells (yellow arrowheads) surrounded with TGC. DAPI (DNA) 
staining is in blue and phospho-histone H3 (P-H3) in pink. (b) A proportion of TGC cells display nuclear aberrancies 
(yellow arrows) in Aurkb(–/–) embryos. (c) Scatter dot-plot quantification of DNA content of TGC in  Aurkb(+/+) n=2 and 
Aurkb(–/–) n=2. DAPI (DNA) staining is in blue and phospho-histone H3 (P-H3) in pink Scale bar, 50m. 
 
36a). During mitosis, Aurora B-deficient cells display abnormal spindles with a strong 
concentration of tubulin in the poles and lack of bipolar fibers (Figure 36b). Multipolar spindles are 
also frequently observed suggesting either a defect in organizing bipolar spindles or the presence of 
polyploidy cells. In addition, all these mitotic figures display misaligned chromosomes (Figure 
36b) confirming the role of Aurora B in promoting proper chromosome alignment during mitosis. 
4.3.3 Aurora B-deficient ES cells arrest at prometaphase with a functional SAC and 
mislocalization of the CPC 
To check if the arrest in prometaphase is a consequence of having a functional SAC we performed 
immunofluorescence to detect Mad2 in unattached kinetochores. Indeed, we observed that Mad2 is 
present at the kinetochores of misaligned chromosomes in mutant cells indicating a functional and 
robust SAC in these cells (Figure 37a). In addition, we detected positive staining for Cyclin B1 
indicating that the APC/C is not active as a consequence of the SAC. Finally, to determine whether 
these phenotypes are a consequence of an abnormal CPC distribution we tested Incenp localization. 
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Figure 36. Aurora B-null ES cells arrest at PM with misaligned chromosomes and spindle abnormalities. 
Immunofuorescence images of embryos harvested at E2.5 and cultured in vitro for 5 days. (a) Aurora B (green signal) is 
present in mitotic, mainly in metaphases (M), and cytokinesis (C) figures in wild-type (arrows and inset) but not in 
Aurkb(–/–) embryos. In the absence of Aurora B, there is an evident accumulation of mitotic cells, mainly prometaphases 
(PM), (arrowheads and inset) in the ICM . Scale bars, 50 m. (b) Mitotic distribution in the inner cell mass. In wild-type 
cells, Aurora B (green) localizes internal to ACA spots (red or white) during prophase (P) or metaphase (M) due to its 
localization to the inner centromere. Aurora B moves to the central spindle during telophase (T) or to the midbody during 
cytokinesis (C). In Aurkb(–/–) embryos, Aurora B is not detected and these cells display aberrant bipolar spindles with 
misaligned chromosomes (white arrow), as well as monopolar or multipolar spindles. Note the presence of multiple poles 
or isolated -tubulin spots (yellow arrows). Aurora B (Aurkb) staining is shown in green, -tubulin (-tub) in red, anti-
centromeric antigen antibody (ACA) in red or white and DAPI (DNA) in blue. Scale bars, 10m. 
 
Whereas Incenp is properly located at the metaphase plate and midbodies of wild-type cells, we 
were unable to find normal localization of Incenp in Aurora B-null cells (Figure 37b), thus 
suggesting that Aurora B deficiency results in impaired CPC function in advanced blastocysts but 
not in earlier developmental stages. 
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Figure 37. Aurora B-null ES cells arrest at PM with an active SAC and a non-functional CPC. Immunofuorescence 
images of embryos harvested at E2.5 and cultured in vitro for 5 days. (a) Aurkb(–/–) cells show the presence of Mad2 
(green) at the kinetochores during prometaphase (white arrow) or in misaligned chromosomes in incomplete metaphases 
(yellow arrow). Cyclin B1 (CycB-green) is also present in these mitotic figures showing a diffuse expression in some 
cases accompanied by enrichment at the poles. (b) Whereas Incenp is properly localized at the centromeres (arrow), 
midbodies or cytokinesis bridged (not shown) colocalizing with Aurora B (Aurkb-green) in wild-type cells, no Incenp 
signal is observed in Aurora B-null cells. -tubulin (-tub) staining is in red and DAPI (DNA) in blue. Scale bars, 10 m.  
4.4. Aurora C compensates for Aurora B function during early embryonic development 
Since lack of the other CPC components, Incenp, Survivin or Borealin results in early lethality by 
E2.5 (Cutts et al., 1999; Uren et al., 2000; Yamanaka et al., 2008), we wondered whether Aurora B 
can be compensated by other Aurora kinases during early embryonic development. In terms of 
homology, Aurora C is closer to Aurora B than Aurora A (Figure 6). Indeed, Aurora C has been 
previously shown to bind other CPC components and to rescue cellular defects due to lack of 
Aurora B when overexpressed in specific cell lines (Sasai et al., 2004; Slattery et al., 2008; Yan et 
al., 2005).  
 4.4.1 Aurora C is highly expressed in early embryos 
To determine whether Aurora C is able to compensate Aurora B during early development, we first 
checked if Aurora C is expressed during early cell divisions. Since currently available antibodies 
did not work in whole-mount immunofluorescence in mouse embryos, we quantified Aurora C 
expression in early embryos by real-time PCR or in post-implantation embryos by 
immunohistochemistry. As depicted in Figure 38a,b, Aurora C is detected in early embryos (2-cell 
stage and morulas) but it is not expressed in late embryos (E14.5) or implanted embryos (E7.5) as 
examined by RT-PCR or immunostaining in sections. As control, we detected Aurora C expression 
in testis by both techniques, RT-PCR and immunostaining, as reported previously (Hu et al., 2000; 
Kimmins et al., 2007; Tang et al., 2006). Similar data indicating expression of Aurora C in early  
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Figure 38. Aurora C is expressed in the early embryonic divisions. (a) Expression of Aurora C at the 2-cell stage, morula, 
mid-gestation or adult tissues as measured by real-time RT-PCR. mRNA levels were normalized versus the expression 
of GADPH. (b) Detection of Aurora C by immunohistochemistry in sections (E7.5) from wild-type (left) or Aurora B-
deficient (middle) post-implantation embryos indicating lack of expression at this stage. Aurora C is not detected in most 
adult tissues but it is highly expressed in germ cells of the testis. (c) Published expression profiles from GNF SymAtlas 
(http://biogps.gnf.org/) showing Aurora C expression specifically in the testis and testis cell lines (left), and in oocytes and 
fertilized eggs (right). Note that there is no Aurora C expression in blastocysts, nor in implanted embryos (E6.5-10.5) or 
in 3T3 cells. 
 
embryos but not in later stages can be obtained from published expression profiles (Hamatani et al., 
2004) (Figure 38c from GNF SymAtlas webpage http://biogps.gnf.org/). 
4.4.2 Inhibition of Aurora B/C results in a severe arrest in early embryos 
We then addressed whether Aurora C may complement Aurora B funcion during early embryonic 
development by using a small molecule inhibitor, ZM447439 (also known as ZM1), that is able to 
specifically inhibit both Aurora B and C kinases (IC50 Aurora B 50 nM ; IC50 Aurora C 250 nM ; 
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IC50 Aurora A 1000 nM ;(Girdler et al., 2006). Wild-type E2 (4-cell) embryos were treated with 
low dosis (2 m) of ZM1 or carrier and analyzed 12 h after addition of the drug. As represented in 
Figure 39a, ZM1 treatment results in a severe arrest at the 4-cell stage in 80% of treated embryos, 
whereas most control embryos progress to the morula stage. Importantly, treatment with ZM1 
results in a phenotype similar to that observed in Aurora B-deficient embryos by E7.5 (Figure 39), 
including prometaphase arrest, misaligned chromosomes and tetraploid or binucleated cells as 
previously reported for this drug (Figure 39b). (Girdler et al., 2006) 
 
Figure 39. Early embryos arrest with mitotic defects after inhibition of Aurora B/C. (a) Sensitivity of early embryos at the 
4-cell stage to ZM1, a small-molecule inhibitor of Aurora B and Aurora C. Treatment of these embryos with 2 M ZM1 
leads to arrest at the 4-cell stage, whereas a parallel treatment with DMSO results in the progression to the morula stage 
after 12 h. (b) Bar graph quantification of percentage of embryos that reach to morula state after 12h treatment with 
2M ZM1. (c) Immunofluorescence analysis indicates a significant accumulation of cells in mitosis (white arrows) or 
poliploid cells (yellow arrows) that have underwent a failed cytokinesis.  (d) The mitotic defects observed after Aurora 
B/C inhibition leads to accumulation of defective mitosis and subsequent poliploidy and to a reduction in the number of 
cells per embryo in ZM1 treated cells. To evaluate inhibition of Aurora B/C kinase acvity we confirmed that 
phosphorylation of histone H3 (P-H3) is significantly reduced in these ZM1-treated mitotic cells although some signal is 
still detected. -tubulin (-tub) staining is in red, phospho-histone H3 (P-H3) in green and DAPI (DNA) in blue. Scale 
bars, 20 m. 
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4.4.3 Aurora C plays a crucial role in driving proper mitosis during early cell divisions 
To further explore the possibility that Aurora C is responsible for supporting cell division during 
the morula and blastocyst stage, we microinjected in the pronucleus of fertilized embryos (E0.5) 
three different short hairpin interfering RNAs (shRNAs) specific for Aurora B or Aurora C kinases 
along with a reporter plasmid that expresses the green fluorescent protein fused to histone H2B 
(Figure 40a). One day after microinjection, most embryos were at the 2-cell stage and expressed 
the fusion protein GFP-H2B in the nucleus of each cell (Figure 40b). Efficient silencing was 
confirmed measuring transcripts levels three days after microinjection (Figure 40a). By E2.5, most 
embryos injected with a shRNA against luciferase (shluc) or Aurora B (shAurB) progressed 
normally forming morulas with 4-8 cells. However, most embryos injected with Aurora C shRNAs 
(shAurC) or a combination of Aurora B and Aurora C shRNAs were either arrested at the 2-cell 
stage (Figure 40b). These embryos, but not the embryos injected with shluc or shAurB constructs, 
displayed a high number of mitotic figures, mostly PM or M by E2.5 (Figure 40c) as previously 
described in the Aurora B-deficient inner cell mass. These abnormal divisions frequently result in 
chromosomal bridges and giant nuclei suggesting an ultimate defect in cytokinesis (Figure 40c) 
resulting in an arrest at the 2-4 cell stage (Figure 40d). All together, these results suggest that 
Aurora C, but not Aurora B, has a crucial role in driving proper mitosis during early embryonic 
development. 
5. Essential functions of Aurora B in G1/S progression and mitosis 
Loss-of-function studies of mammalian Aurora B have used RNA interference or chemical 
inhibitors of this kinase resulting in a clear characterization of its role in chromosome alignment 
and cytokinesys (Ruchaud et al., 2007) .However, these studies have the caveat that elimination of 
the protein is never complete and residual kinase activity may support certain activities. To analyze 
the cellular effects of the acute deletion of Aurora B in cultured cells we took advantage of the 
conditional Aurkb(lox) allele. Primary Aurkb(lox/lox) MEFs were isolated from E14.5 embryos and 
cultured in complete medium. Importantly, Aurora C is not expressed in MEFs as it is not 
expressed in mid-gestation embryos nor in immortal fibroblasts derived from them as depicted 
previously (Figure 38). Confluent MEFs were infected with adenoviruses expressing either GFP 
(AdGFP) or the Cre recombinase (AdCre) as indicated in Figure 41a. Expression of Cre, but not 
GFP, results in an almost complete deletion of exons 2-6 [Aurkb() allele; Figure 41b]. 
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Figure 40 (previous page) Knock-down of Aurora C but not Aurora B results in cell cycle arrest in early embryonic 
development. (a) Schematic representation of the protocol followed for knock down of Aurora B and/or Aurora C in 
zygotes. Embryos were isolated at E0.5 and microinjected with vectors expressing shRNAs against luciferase (shLuc) 
and Aurora B (shAurB) and/or Aurora C (shAurC), as well as a plasmid expressing H2B-GFP. These embryos were 
analyzed at E1.5, E2.5 or E3.5 by fluorescent microscopy or quantitative (q)RT-PCR. qRT-PCR analysis shows a clear 
downregulation of Aurora C in these assays and a modest reduction of Aurora B. However, it is important to note that 
Aurora B mRNA levels are minimum at this stage and close to the background of mRNA detection in these assays. (b) 
Confocal microscopy in vivo images (combined bright field and green fluorescence) of embryos treated with these 
shRNAs indicating an arrest at the 2-4 cell stage in embryos treated with shAurC, shAurB-shAurC, but not shAurB or 
embryos treated with shRNAs against luciferase (not shown). Scale bars, 100 m. (c) Knock down of Aurora C (shC) or 
Aurora B+Aurora C (shB+C) results in a significant increase in mitotic cells in most cases showing misaligned 
chromosomes (white arrows) by E2.5. By E3.5, most treated embryos display polyploid cells as well as cytokinesis 
bridges or micronuclei (arrows). These later abnormalities are not observed in shB cells or cells microinjected with 
shRNAs against luciferase (not shown). (d) Immunofluorescence analysis of these embryos by E3.5 shows mitotic 
aberrations and apoptotic figures after microinjection of shAurC or shAurB+AurC. These embryos arrested at the 2- or 4-
cell stage whereas shAurB or shLuc embryos show an average of 8 cells per embryo.-tubulin (-tub) staining is in red, 
H2B-GFP signal in green and DAPI (DNA) in blue. Scale bars, 20 m 
5.1 Aurora B depletion in MEFs provokes a delay in the entry into S-phase  
To analyze the initial phases of the cell cycle in Aurkb(lox/lox) MEFs, we first removed the serum 
during 2 days, re-plate the cells at low density and re-stimulate the cell cycle by adding 10%FBS 
(t=0). In primary MEFs, DNA replication starts at about 12 h with a peak in 18-20 h (Garcia-
Higuera et al., 2008). Whereas infection of Aurkb(lox/lox) cells with AdGFP resulted in the normal 
pattern on DNA replication, AdCre-infected cells showed a dramatic delay (14% cells in S-phase 
versus 33% in AdGFP cells 18 h after serum stimulation) in the entry into S-phase (Figure 42a). 
This effect was also observed by analyzing DNA replication by a brief pulse (20 min) of BrdU. Six 
hours later, BrdU incorporation is reduced in AdGFP cells since these cells are exiting from S-
phase. Expression of Cre however results in increased BrdU incorporation at 24 h (Figure 42b) 
 
Figure 41. Acute deletion of Aurora B in MEFs. (a) Schematic representation of the protocol followed for acute deletion 
of Aurora B in MEFs. Primary (passage 2) Aurkb(lox/lox) MEFs were seeded at 80% confluence and allowed to form a 
completely confluent culture during 2 days. These cells were then cultured in 0.1% FBS (for G1/S assays) or 10% FBS 
(for analysis of mitosis) and infected with adenoviruses expressing GFP (AdGFP) or the Cre recombinase (AdCre). Two 
days after the infection, cells were seeded in new plates at low confluence in the presence of 10% FBS to induce entry 
into the cell cycle. The Aurora B/C inhibitor ZM1 was also added at this point to non-infected cells. (b) Expression of Cre, 
but not GFP, results in an efficient deletion of exons 2-6 (see Figure 18) as detected by PCR amplification of the 
Aurkb(lox) conditional allele or the resulting Aurkb() null allele.  
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suggesting that the absence of Aurora B provokes a delay in the entry into S-phase, rather than a 
complete impairment in DNA replication. Importantly, these phenotypes can be recapitulated by 
treating non-infected Aurkb(lox/lox) cells with the Aurora B/C inhibitor ZM1 at the time they are 
seeded at low density (t=0). ZM1-treated cells also display a significant delay in S-phase entry and 
BrdU incorporation similar to that observed in Aurkb() cells (Figure 42a,b). 
5.2 Aurora B deficiency interfere with G1-S progression in vivo after partial hepatectomy 
To test whether these defects in S-phase could also be observed in vivo, we induced cell cycle entry 
in adult Aurkb(+/–) mice by submitting Aurkb(+/+) and  Aurkb(+/–) mice to hepatectomy assays, a 
model commonly used for synchronized G1/S progression in vivo. After excision of 2/3 of the 
liver, hepatocytes usually take 1.5-2 days to synthesize new DNA in a highly synchronized manner 
(Mitchell and Willenbring, 2008). We tested BrdU incorporation 4 h, 12 h, 48 h and 6 days after 
 
 
Figure 42. Aurora B is required for the G1/S transition in MEFs. (a) Progression into S-phase at different time points after 
addition of serum. Bar graph quantification of Aurkb(lox/lox) MEFs infected with AdGFP or AdCre or treated with ZM1 
and analyzed by propidium iodide staining showing a dramatic delay in S-phase entry upon the genetic ablation or 
chemical inactivation of Aurora B. Representative FACS profiles of these samples at time serum was added (t=0) or 18 h 
after mitogenic stimulation. (b) Incorporation of BrdU was also tested by treating these cultures with a short (20 min) 
pulse of BrdU before harvesting the cells. BrdU incorporation was analyzed by immunofluorescence with specific 
antibodies (green). DAPI (DNA) is shown in red. Bar graph quantification of percentage of BrdU positive cells revealing a 
delay in entering into S phase in Aurkb(lox/lox) MEFs infected with AdCre or treated with ZM1 and not in control Ad-GFP 
infected cells.  
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partial hepatectomy. As depicted in Figure 43a, no BrdU incorporation is observed before 12 h. A 
clear peak in DNA synthesis (6.5% BrdU-positive cells) is observed in Aurkb(+/+) 48 h after 
partial hepatectomy. Aurkb(+/–) mice, however, do not enter S-phase during these first two days 
and only display a reduced (0.5%) number of BrdU-positive cells. Similar results are observed by 
quantifying Ki67 signal or mitotic figures in these samples (Figure 43b). During liver regeneration 
we observed a similar decrease in binucleated hepatocytes both in Aurkb(+/+) and Aurkb(+/–) mice 
indicating no further problems in cell division in these cells despite the initial problems in entering 
into S phase (Figure 43c). Indeed, heterozygous mice regenerate a significant percentage of 
dissected liver in 6 days although these mice frequently display abnormal tissue structure and 
necrotic areas suggesting an inefficient response to these stress conditions (Figure 43c,d).  
5.3 Aurora B may regulate G1-S transition by modulation of the mTOR pathway or p21 
levels  
Although a role for Aurora B in G1/S progression has not been clearly established, some recent 
evidences suggest that Aurora B is able to modulate the mTOR pathway in T lymphocytes (Song et 
al., 2007) and may directly phosphorylate the retinoblastoma protein (pRb) at Ser780 (Nair et al., 
2009). In addition, we found that Survivin deletion in cell lines provokes G1 arrest accompanied by 
induction of p21
Cip1
, a p53 effector of cell cycle arrest (Yang et al., 2004). We therefore tested 
phosphorylation of the mTOR substrate p70S6 kinase (p70S6K) as well as phosphorylation of pRb 
and induction of p21
Cip1
 either in Aurora B-depleted MEFs and in Aurkb(+/–) livers after 
hepatectomy.  
5.3.1 In Aurora B-depleted MEFs 
Despite the significant defects in the G1/S progression of Aurora B-null cells, we detected minor 
differences in the previous markers. Specifically, the p70S6K-T380 phospho signal is decreased in 
Aurora B deficient cells 10 h after entry into the cell cycle; and p21
Cip1
 cell cycle inhibitor levels 
are slightly increased in the cell cycle, soon after cell cycle entry (Figure 44a).  
5.3.2 In Aurkb(+/–) livers after hepatectomy 
We also tested markers of the activation of the mTOR, pRb or p53 pathways at shorter times after 
hepatectomy. As represented in Figure 44b, phosphorylation of p70S6K is decreased in Aurkb(+/–) 
mice 4 h [a peak for this critical phosphorylation in this system; (Haga et al., 2009)] after partial 
hepatectomy. No clear differences in pRb phosphorylation are observed whereas p21
Cip1
 is also  
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Figure 43. Aurora B is required for the G1/S transition in vivo after partial hepatectomy. (a) BrdU incorporation in vivo 
after 2/3 partial hepatectomy in Aurkb(+/+) n=3 and Aurkb(+/–) mice n=2. The percentage of BrdU-positive cells (as 
detected by immunohistochemistry) is shown 4, 12 and 48 h as well as 6 days after hepatectomy. Incorporation of BrdU 
is highly reduced by 48 h in Aurora B-mutant mice. (b) Representative images of proliferation markers (BrdU 
incorporation and Ki67 levels) 48 h after hepatectomy. Quantification of Ki67 or mitotic figures in these samples also 
indicates a significant reduction in cell cycle entry and progression in Aurkb(+/–) mice. (c,d) Normal recovery of liver 
mass after partial-hepatectomy in Aurkb(+/–) mice. (c) Bar graphs quantifications of percentage of binucleated 
hepatocytes 2 and 6 days after hepatectomy and final liver regeneration in Aurkb(+/+) and Aurkb(+/–) mice. Similar 
reduction is observed in binucleated hepatocytes from Aurkb(+/+) and Aurkb(+/–) mice and equivalent potential of the 
livers to recover its mass. (d) Gross appearance of regenerated livers 6 days after hepatectomy and HE&E stained liver 
sections revealing almost normal recovery of Aurkb(+/–) livers but suggesting inefficient responses to stress conditions 
due to the presence of necrotic areas (asterisk) and abnormal tissue structures (arrows) in Aurkb(+/–) livers. Scale bars, 
100 m 
 
partially upregulated in Aurkb(+/–) livers. On the other hand, phosphorylation of p70S6K peaks at 
12 h in these Aurkb(+/–) mice suggesting a delay in the activation of the mTOR pathway in these 
liver cells. All together, these results indicate that deficiency in Aurora B may interfere with G1/S 
progression at least partially by modulating the mTOR pathway or the levels of the p53 effector 
p21
Cip1
 in different cell types. 
Results 
 
74 
 
 
 
 
Figure 44. Aurora B may interfere with G1/S progression by modulating mTOR pathway or p21Cip1 levels. (a) 
Immunodetection of phospho-specific markers for the mTOR (phospho-p70S6K at Thr389) or pRB (phospo-pRb at 
Ser780) pathways 2, 10 or 18 h after stimulation with serum. The expression of the p53 effector p21Cip1 is slightly 
increased in Aurkb() cells. Immunodetection of Akt or -actin was used as a loading control. (b) Immunodetection of 
phospho-p70S6K, phospo-pRb and p21Cip1 levels in Aurkb(+/+) and Aurkb(+/–) livers after different time points after 
partial hepatectomy. Immunodetection of -actin was used as a loading control. 
5.4 Depletion of Aurora B in MEFs results in multiple nuclei, micronuclei and apoptosis 
In spite of the delay in S-phase entry, Aurora B-deficient MEFs continue cycling and are able to 
undergo mitosis. To explore new possible roles of Aurora B during the cell cycle, we performed 
acute deletion of Aurora B in Aurkb(lox/lox) cells, following the same protocol as before (Figure 
41), and we analysed this cell population after two or three rounds of division (48 and 72h after 
infection). Note that doubling cycle is about 24h in MEFs. Seventy-two hours after expression of 
the Cre recombinase, Aurora B-deficient MEFs accumulate as 4N or >4N DNA content cells as 
depicted in Figure 45a. Examination of these cultures at 48 h by immunofluorescence indicates an 
efficient elimination of Aurora B at the protein level in Cre-infected cells (Figure 45b). After two 
rounds of division, lack of Aurora B is accompanied by a massive accumulation of abnormalities 
including multiple nuclei, as well as micronuclei and apoptotic figures (Figure 45c,d). About 40% 
of the culture accumulates as abnormal interphase cells including multinucleated cells, cells with 
micronuclei and apoptotic figures (versus 13% of AdGFP cells showing these phenotypes; Figure 
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45c). These defects are likely a consequence of abnormal cell divisions and, in fact, the few 
cytokinesis figures observed in AdCre-infected cells frequently display chromosomal bridges 
suggesting abnormal segregation of chromosomes during mitosis (Figure 45d). 
 
Figure 45. Acute deletion of Aurora B results in polyploidy and cell death. (a) Infection with AdCre in primary MEFs 
results in an accumulation of 4N and >4N cells 72 after the exit from quiescence as detected by flow cytometry. (b) 
Examination of these cultures by immunofluorescence at 48 h indicates efficient depletion of Aurora B (green signal) in 
AdCre-infected cells. These mutant cells display aberrant morphologies as indentified by staining with -tubulin (-tub) 
antibodies (red) and DAPI (DNA) staining (blue). (c) Aurkb() primary MEFs display an accumulation of abnormal 
interphase cells (bar graphs) including cells with several nuclei or micronucleai (see picture) and apoptotic cells. n 
indicates the number of cells counted for each genotype in (c) and (d). (d) In addition, there is a dramatic reduction in 
cytokinesis figures suggesting a defect in the later stages of cell division. The remaining cytokinesis figures in 
Aurkb() cells are usally abnormal with long chromosomal bridges (arrows) between the two daughter cells. Scale 
bars, 10 m 
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5.5 Aurora B-deficient MEFs accumulate in prophase / prometaphase with misaligned 
chromosomes and spindle aberrations 
Whereas most Aurora B-deficient cells accumulate in an abnormal 4N or >4N interphase stage with 
decondensed chromosomes, only 1.2% of these cells are in mitosis compared to 2.8% in control 
cultures (Figure 46a) suggesting a premature exit from mitosis in AdCre-infected cells. In fact, in 
contrast to normal mitotic distribution of control cells, Aurora B-deficient cells are characterized by 
an accumulation in P and PM with very few cells in metaphase or post-metaphase stages in 
agreement with the decreased cytokinesis observed in these cells (Figure 45d and 46a). Most of 
these mitotic figures are abnormal and present misaligned chromosomes and spindle aberrations. 
About 82% of mitotic figures display spindle aberrations in the absence of Aurora B (Figure 46b). 
These aberrations include monopolar (12% mitotic cells) and multipolar (50% mitotic cells) 
spindles in the majority of the cases accompanied by misaligned chromosomes. A detailed 
observation of the spindle structure detects additional abnormalities in microtubule behaviour in 
mitotic Aurkb() cells. About 25% of these Aurora B-deficient cells display a novel phenotype 
that consists on an accumulation of -tubulin asters that are or are not connected to chromosomes 
(„multiaster‟ phenotype; see arrowheads in Figure 45b and 46b).  
 
Figure 46. Aurora B-depleted MEFs accumulate in P/PM with chromosome misalignment and spindle aberrations. (a) 
Bar graphs quantification of mitotic index and mitotic distribution. Ablation of Aurora B results in a decrease in the total 
percentage of mitotic cells (condensed chromosomes) in these cultures. Most Aurkb(/) mitotic cells accumulate in 
prophase (P) or prometaphase (PM) with a dramatic reduction in metaphase (M), anaphase (A) or telophase (T) stages. 
(b) Immunoflorescence images showing that most P and PM are abnormal with abundant misaligned chromosomes 
(arrows). In addition, Aurkb(/) cells display severe spindle abnormalities as quantified in the bar graph. These cells 
show a dramatic increase of monopolar and multipolar spindles accompanied by isolated -tubulin spots (multiaster 
phenotype; arrowheads) that in some cases display a robust nucleation of microtubules (see bottom-right panel). -
tubulin (-tub) staining is in red and DAPI (DNA) in blue. Scale bars, 10m 
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5.6 Depletion of Aurora B in MEFs leads to accumulation of -tubulin asters and/or 
supernumerary MTOCs 
The „multiaster‟ phenotype is characterized by the presence of asters that contain an increase 
density of astral microtubules that are not observed in the spindle poles of Ad-GFP-infected cells. 
Whereas Aurkb(lox/lox) MEFs display two clear -tubulin-positive microtubule-organizing centers 
(MTOC) during mitosis, the number of -tubulin MTOCs can reach up to 12-13 in Aurkb(/) cells 
(Figure 47a). The multiple MTOCs may also explain monopolar spindles as these figures 
frequently contain multiple -tubulin spots grouped around the single pole (Figure 47b). In many 
cases, the supernumerary MTOCs are not connected to the chromosomes and, yet, they display a 
significant ability to nucleate microtubules. Since these MTOCs are observed 48 h after entry into 
the cell cycle, they are likely not a consequence of accumulating multiple cell divisions during this 
time. In fact, we counted chromosomes using ACA as a centromeric marker and all the analyzed 
cells with ≥12 MTOCs (n=6) were either 4N or 8N (Figure 47c), suggesting the presence of diploid 
or tetraploid cells but not a further increase in the ploidy of these cells.  
5.7 Aurora B-deficient MEFs show a weak mitotic checkpoint that results defective after 
spindle partition 
To explain whether the accelerated mitotic exit observed in Aurkb(/) cells is a consequence of 
having a deficient SAC, we checked Mad2 kinetochore localization 48h after expression of the Cre 
recombinase. Whereas Mad2 signal is clearly observed in PM figures of AdGFP-infected cells, we 
were not able to find detectable Mad2 signal in any of these abnormal PM in Aurora B-deficient 
cells (Figure 48a) thus suggesting that, despite these abnormalities, the SAC is inactive. We next 
tested whether spindle abnormalities were present in cyclin B1-positive or negative cells. Cyclin 
B1 shows a diffuse localization in mitotic Aurkb(lox/lox) cells before metaphase but it is degraded 
by the APC/C in the metaphase-to-anaphase transition, once the SAC is extinguished. As depicted 
in Figure 48b, cyclin B1 is also present in some PM Aurkb(/) cells. These cyclin B1-positive 
cells usually display a bipolar or pseudo-bipolar spindle with misaligned chromosomes. In some of 
these poles, -tubulin is normally concentrated. However, many other cyclin B1-positive cells 
display an unfocused distribution of -tubulin or fragmented poles with a few -tubulin spots near-
by. Cyclin B1-negative cells on the other hand, display multiple -tubulin spots distributed all over 
the cell including distant areas from chromosomes (Figure 48b).  
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Figure 47. Ablation of Aurora B results in the formation of multiple -tubulin-positive microtubule organizing centers 
(MTOC) and aberrant astral microtubule nucleation. (a) Immunofluorescence detection of -tubulin (white) in Aurkb(/) 
cells indicates the presence of multiple -tubulin spots that are or are not part of the spindle structure. This -tubulin 
material is accompanied by dense microtubule asters and we refer to it as microtubule organizing center (MTOC). 
Phosphorylation of histone H3 (P-H3 in green) is reduced but not absent in Aurora B-deficient MEFs similar to that 
observed in ZM1-treated embryos (see Figure 30). (b) Monopolar spindles in Aurora B-deficient cells are usually formed 
by multiple -tubulin spots. Aurora B (Aurkb) staining is in green. (c) Parallel examination of the number of MTOCs using 
-tubulin (red) and the number of chromosomes using ACA (green) revealing a nearly tetraploid cell with 12 MTOCs. -
tubulin (-tub) staining is in red and DAPI (DNA) in blue. Scale bars, 10 m 
 
Altogether, these results indicate that lack of Aurora B results in chromosome 
misalignment during a transient cyclin B1-positive PM and a concomitant fragmentation of spindle 
poles. After spindle partition, cyclin B1 dissapear and Mad2 is delocalized from the kinetochores, 
resulting in a defective SAC, and the multiple -tubulin-positive MTOCs continue to nucleate 
microtubules. These cells subsequently exit from mitosis directly from these aberrant PM to form 
cells with several nuclei or micronuclei. 
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Figure 48. Fragmentation of spindle poles in Aurora B-deficient MEFs leads to disappearance of Cyclin B1 and to a 
defective SAC. Immunofluorescence detection of SAC markers Mad2 and Cyclin B1 (CycB1) in Aurkb(lox/lox) and 
Aurkb(/) MEFs. (a) Whereas control cells in PM display Mad2 (red) staining at the kinetochores, this SAC marker is 
not detected in PM figures deficient in Aurora B. (b) The number of -tubulin (red) spots increases from cyclin B1-positive 
(green) to cyclin B1-negative cells. Aurkb(lox/lox) cells display a clear bipolar spindle with -tubulin spots in the poles. 
Some Aurkb() cells are positive for Cyclin B1 staining. These cells usually display aberrant PM figures with bipolar 
spindles (Cyclin B1-positive; top panels) and two focused spots of -tubulin. Occasionally, additional small -tubulin spots 
is observed (white arrow). Other Cyclin B1-positive cells (bottom panels) display pseudo-bipolar spindles in which the -
tubulin spots are fragmented (yellow arrow) or seem to disaggregate (pink arrow). In Cyclin B1-negative cells, multiple -
tubulin spots are observed that are either forming part of a multipolar spindle or completely separated (asterisks) from 
the multipolar spindle. In the images, 5 (top panels) or 12 (bottom panels) MTOCs are observed in Cyclin B1-negative 
cells. DAPI (DNA) staining is in blue. Scale bars, 10 m. 
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Discussion 
1. Regulation of Aurora B by SUMOylation 
In budding yeast, over 500 potential SUMOylation targets have been identified through systematic 
screens (Hannich et al., 2005; Panse et al., 2004; Wohlschlegel et al., 2004; Wykoff and O'Shea, 
2005). Global mapping of the SUMO network by protein-protein interactions and genetic networks 
has linked SUMOylation to fifteen different broad biological processes. One of these processes is 
chromosome segregation and cell cycle (Makhnevych et al., 2009). In the last years, the SUMO 
pathway has been implicated in several aspects of mitosis, including chromosome structure, cell 
cycle progression, kinetochore function and cytokinesis (Dasso, 2008). Global inhibition of 
SUMOylation in mammalian cells has been reported to cause cells to arrest in mitosis (Zhang et al., 
2008b) revealing the importance of this post-translational modification for mitotic progression. 
Indeed, the CPC has been intensively proposed to be regulated by SUMOylation. In this line, the 
CPC members Incenp and Survivin in yeast (Sli15 and Bir1, respectively) have been proposed to 
be modified by SUMO (Montpetit et al., 2006; Wohlschlegel et al., 2004). Similarly, Borealin has 
been shown to be modified by SUMO-2/-3 in human cells (Klein et al., 2009). However, the 
functional impact of SUMOylation on CPC activity remains to be elucidated. 
In this work, we have identified and analyzed the consequences of SUMO modification of 
Aurora B, an essential regulator of mitosis. By the use of bioinformatics tools we found a 
consensus sequence for SUMO modification in Aurora B, which is highly conserved among 
species and in the other members of the Aurora family. Our data indicate that mouse Aurora B is 
susceptible to be SUMOylated in vivo by the three SUMO isoforms at lysine 207 (K207). Recent 
work has described that Aurora B was not significantly modified by SUMO-1 in vitro and that it is 
not able to interact with E2 SUMO-conjugating enzyme Ubc9 or SUMO isoforms in yeast two-
hybrid assays (Klein et al., 2009). One explanation to these apparent contradictory results is that 
Aurora B conformation in vivo can be dramatically distinct than in vitro. Indeed, using our in vivo 
approach, Aurora B seems to be modified by SUMO when immunoprecipated from cell extracts 
where the CPC integrity is maintained. Moreover, crystalization of an active Aurora B protein was 
only successful in complex with IN-box segment of Incenp (Sessa, 2005). Using this crystal 
structure we have simulated the interaction between Aurora B and SUMO-2 in collaboration with 
Guillermo Montoya (CNIO) (Figure 49). The simulation showed that Aurora B SUMOylation is 
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possible and that Incenp may be necessary for it. Therefore the protein-protein interactions among 
the CPC members seem to be necessary to efficiently SUMOylate Aurora B.  
An increasing number of works have associated SUMOylation and mitosis regulation. 
Borealin, a CPC member,  is dynamically modified by SUMO-2/-3 in a conjugation-deconjugation 
cycle catalyze by the E3 SUMO-ligase RanBP2 and the SUMO-protease SENP3 (Klein et al., 
2009). According to observations in Xenopus egg extracts and human cells, SUMO-2/-3 is found at 
centromeres and chromatin during prometaphase/metaphase, whereas SUMO-1 localizes to the 
mitotic spindle and the spindle midzone at same stages (Ayaydin and Dasso, 2004; Azuma and 
Dasso, 2002; Zhang et al., 2008b). These data suggest that centromeric proteins, such as Aurora B, 
would be preferentially modified by SUMO-2/-3. In addition, RanBP2 associates with 
Topoisomerase II, a known Aurora B substrate, and the CPC in mitosis and is essential for Borealin 
SUMOylation in vivo (Dawlaty et al., 2008; Klein et al., 2009). Thus, it is possible that RanBP2 
may also serve as the E3 SUMO-ligase for Aurora B modification. Redarding SUMO 
deconjugation, there are three SUMO-proteases SENP-2, SENP-3 and SENP-5 that have been 
implicated in mitotic progression. Overexpression of SENP-2 results in global inhibition of 
SUMOylation during mitosis and persistent activation of the spindle checkpoint but does not affect 
the localization of Aurora B and other centromere-associated proteins (Zhang et al., 2008b).  
SENP-3 acts preferentially toward SUMO-2/-3 conjugates and catalyzes the removal of SUMO 
peptides from Borealin both in vivo and in vitro (Klein et al., 2009). However, its depletion does 
not interfere with CPC targeting or activity arguing against a deregulation of Aurora B. Finally, 
depletion of SENP-5 causes cytokinesis defects but does not disturb CPC localization or function 
(Di Bacco et al., 2006; Klein et al., 2009). Regarding Aurora B, further studies will be necessary to 
determine the SUMO isoform, ligase and protease that specifically participate in the control of 
Aurora B modification. 
But, at the molecular level, how is modulating SUMO Aurora B function? SUMOylation 
alters protein surfaces and thereby positively or negatively influences interactions with other 
macromolecules (Geiss-Friedlander and Melchior, 2007). Thus, SUMOylation can interfere with or 
promote protein-protein interactions and provoke conformational changes in the modified target. 
The consequences of these molecular changes may influence in vivo any single aspect of a target 
protein, including a) localization, b) stability or c) activity. As shown in this work, SUMOylation 
of Aurora B seems to regulate the dynamics of Aurora B localization at the centromeres. Rescue 
experiments performed with a SUMO-deficient form (K207R) of Aurora B demonstrates that both 
Aurora B and Incenp fail to concentrate in inner centromeres during prometaphase/metaphase. This 
result suggests that lack of Aurora B SUMOylation affects the whole CPC localization. Indeed, the 
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CPC members are physically and functionally interpendent and perturbation of any member of the 
complex may delocalize the others (Gassmann et al., 2004; Jeyaprakash et al., 2007). Other 
examples of mitotic proteins whose localization at kinetochores/centromeres is regulated by SUMO 
are the kinesin CENP-E and the GTPase-activating protein RanGAP1 (Joseph et al., 2002; Zhang et 
al., 2008b).  
Although we have not explored the hypothesis that SUMOylation of Aurora B might be 
able to regulate its stability,  it is possible that this process take place through the recruitment of E3 
ubiquitin-ligases (Geoffroy and Hay, 2009). Recent studies have shown that ubiquitination of 
Aurora B by the Cul3-Klhl9/Klhl13 E3 ligase complex during early mitosis might serve as a signal 
for its removal from chromosomes since in the absence of Cul3-Klhl9/Klhl13 activity, Aurora B is 
not ubiquitinated and accumulates on chromosomes (Sumara et al., 2007). Due to the similar 
phenotypes observed upon defective SUMOylation and failed Cul3-Klhl9/Klhl13 ubiquitination, 
one can think that both processes may be linked together. An attractive possibility is that CPC 
SUMOylation may act as a signal to recruit E3 ubiquitin-ligases directing the ubiquitination of the 
CPC members themselves and possibly other centromere proteins. Indeed, the fission yeast Aurora 
kinase (Ark1p) interacts with two RING-finger proteins that possess SUMO interacting motifs 
(SIMs), called Rfp1p and Rfp2p (Sun et al., 2007). These E3 ubiquitin-ligases recognize 
SUMOylated proteins and heterodimerize with Slx8, another RING-finger protein, to form a 
functional ubiquitin ligase (Sun et al., 2007; Uzunova et al., 2007). Therefore, it is possible that in 
mammals SUMOylation of Aurora B may facilitate the formation of a functional Cul3-
Klhl9/Klhl13 ligase complex during mitosis. Indeed, we have found three predicted SIMs in each 
coadaptor, Klhl9 and Klhl13, and one additional SIM in the Cul3-ligase that are conserved in 
human and mouse in all cases (data not shown). Future experiments are necessary to test and 
validate this hypothesis.  
SUMOylation of Aurora B may also modulate kinase activity. Surprinsingly, rescue 
experiments with a kinase-dead mutant D205A results in phenotypes that are similar to the ones 
obtained for the K207R Aurora B mutant. A detailed analysis of Aurora B crystal structure reveals 
that the mutated D205 residue is only two aminoacids upstream the SUMO-binding site (K207) and 
that both residues share the same structural loop (Figure 49b). It is, therefore, possible that D205A 
can behave as a kinase-dead mutant and additionally as a partial SUMO-dead mutant. It has been 
recently confirmed that Aurora B substrates phosphorylation depends on the distance of the 
substrate from the kinase at the inner centromere (Liu et al., 2009). This regulation, in turn, has 
probed to be an efficient way to correct improper microtubule-kinetochore attachments (Andrews, 
2004; Knowlton et al., 2006). Here, we show that a SUMO-deficient Aurora B form is more active 
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than its wild-type counterpart in vitro but fails to phosphorylate CENP-A in vivo. This result can be 
explained by the fact that centromeric mislocalization of Aurora B can impede the encounter of the 
kinase with its substrates failing to phosphorylate them in vivo but obviously not in vitro. The in 
vitro kinase assay performed with immunoprecipated proteins is really interesting as it can explain 
many of the phenotypes observed with the different mutants. Based on our kinase assays, the 
SUMO-deficient form (K207R) is probably a hyperactive mutant. This result is certainly surprising 
given that, so far, no hyperactive mutants have been described for Aurora B, (T232E is not a 
hyperactive mutant, (Yasui, 2004). A detailed examination of the crystal structure reveals that 
SUMO binding may block the entrance of ATP to the kinase and/or the transference of phosphate 
groups to a given substrate (Figure 49a). Therefore, it is reasonable to think that lack of 
SUMOylation facilitates ATP binding and transfer. This increase in the kinase activity plus the 
delocalization of the kinase during early mitosis can account for the cellular defects and the 
impaired viability observed upon transient and stable expression of a SUMO-deficient form. On the 
other hand, both kinase-dead mutants (K111M and D205A) behave in distinct manner. This is 
probably due to the different grade of inhibition obtained with each mutation. Hence, K111M is a 
partial kinase-dead mutant and this residual activity does not compromise cell viability. However, 
D205A mutation renders almost complete inactivation of the kinase leading to high rates of 
polyploidy when overexpressed and compromising cell viability. 
Importantly, Aurora B activity also correlates with its ability to promote tumorigenesis by 
enhancing oncogenic Ras transformation. Thus, our results show that an inactive Aurora B form 
(D205A) poorly cooperates with H-Ras as suggested previously (Kanda et al., 2005); whereas the 
possibly hyperactive Aurora B form (K207R) was able to increase H-Ras oncogenic potential 
significantly more than its wild-type counterpart. This link between SUMOylation and kinase 
activity may have relevant implications in tumorogenesis that deserve further research.     
2. New models for studying Aurora B function and therapeutic value in vivo 
Genetically modified mouse models are a highly valuable tool that permits a better understanding 
of the function of a particular gene in an organism. They constitute one of the best  model systems 
for cancer investigations (Frese and Tuveson, 2007). Despite the diverse technical approaches used, 
genetically modified mouse models can be classified as either transgenic or endogenous. The first 
ones consist on mutant mice that express genes in a non-physiological manner owing to ectopic 
promoter and enhancer elements. In its original and simplest form, transgenic mice are generated 
by pronuclear injection of cDNA constructs that contain promoter elements designed to restrict  
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Figure 49. Modeling Aurora B-SUMO-2 covalent interaction. (a) Crystal structures of human SUMO-2 (Reverter and 
Lima, 2006; Sessa, 2005) and xenopus Aurora B in complex with IN-box segment of Incenp (Sessa, 2005) were used to 
simulate the interaction of both molecules. SUMO-2 covalently binds to mouse K207 residue (K218 in xenopus crystal 
structure) of Aurora B kinase domain through a finger composed by two glycine residues. By this interaction 
SUMOylation does not affect the binding of Aurora B partner and activator Incenp, but may disturb the transference of 
phosphate groups to its sustrates. (b) Detail of the ATP-binding pocket showing the localization of K111, D205 and K207 
residues (K122, D216 and K218 in xenopus, respectively) used in this study. D205 and K207 share the same structural 
loop while K111 is far from this region interacting with ATP.  
 
tissue tropism. However, owing to the random nature of transgene integration, chromosomal 
positional effects can result in variegation and incomplete penetrance, thus potentially confounding 
results. Therefore, a more controlled insertion of the transgene into a well-characterized 
euchromatic locus has overcome this limitation. An additional improvement of transgenic models 
came with the development of new systems in which it is possible to reversibly control target gene 
expression with exogenous ligands, such as doxycycline or interferon. Endogenous genetically 
modified mouse represent mutant mice that lose the expression of a given gene (knock-out) or 
express a mutant variant of it (knock-in) from their native promoters. Gene knock-out approaches 
entail the replacement of endogenous embryonic stem cell chromatin by a targeting vector that 
disrupts this allele, and were the first methods used to generate such mice. The biggest advantage 
of this approach is that, in contrast to other techniques, such as RNA interference or drug 
inhibition, targeting of a gene of interest can provoke the total elimination. Given the fact that 
germline biallelic disruptions of genes often cause embryonic lethality, the development of 
conditional knockout models has been a significant improvement of these models. Conditional 
mouse systems rely on the use of site-specific recombinases to control the spatiotemporal mutation 
of the genome. The most common conditional system uses the bacteriophage Cre-lox system in 
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which Cre recombinase recognizes a pair of inverted repeat DNA elements, or loxP sites, and 
catalyses recombination resulting in deletion or inversion of the intervening sequence.  
In this project we have generated three different mouse models: a conditional knock-out 
model, a knock-in model in which Aurora B expression has been replaced by β-galactosidase and a 
tetracycline inducible model. The first two models have been used to perform the experiments 
described in this memory (see below), while the inducible model has been recently generated in 
collaboration with WC. Earnshaw‟s laboratory. This model allows the analysis of fine-tuning of 
Aurora B protein in vivo (work in progress).  
Whereas complete inactivation of Aurora B, which was obtained with the Aurkb(–) and 
Aurkb() alleles, leads to embryonic lethality at post implantation stages, its partial inactivation in 
heterozygous mice is associated with a slight increase in spontaneous tumours. The tumours 
formed in these mice occur late in life (>20 months old). The reason of the appearance of these 
tumors is not known. It might be possible that reduced expression of Aurora B could lead to 
accumulation of genomic instability that in turn, may facilitate tumor development in old mice. 
Indeed, chromosome missegregation, errors in spindle assembly and defects in cytokinesis are 
Aurora B loss-of-function phenotypes that have been associated with genomic instability and 
aneuploidy. Given that tumours are formed late in life, we can speculate that mice with reduced 
levels of Aurora B accumulate aneuploidy during life, increasing the probability of neoplastic 
transformation. Similar results have been obtained in mice with reduced expression of mitotic 
checkpoint components. Specifically, mice that are heterozygous for Mad1 and Mad2 develop 
benign lung tumours, whereas CenpE heterozygous animals show an increased incidence of benign 
lung tumours and splenic lymphomas (Iwanaga et al., 2007; Michel et al., 2001; Weaver et al., 
2007). In the near future, we are planning to confirm by FISH technique whether there is an 
increase in genomic instability or aneuploidy in the tumours of Aurora B heterozygous mice.  
Interestlingly, when we exposed Aurora B heterozygous mice to carcinogens or oncogene 
gain of function we did not observe an increase in tumour development but rather, a slight 
reduction in the formation of fibrosarcomas, papillomas and mammary tumors. One explanation for 
these observations is that tumour induction combined with the inherent aneuploidy of these mice 
may result in a rate of genetic instability above a threshold compatible with cell viability. Similar 
results were also observed in CenpE heterozygous mice after exposure to DMBA-TPA treatment 
(Weaver et al., 2007). Another explanation might be that reduced levels of Aurora B in mice 
compromise proliferation under stress conditions, as observed in the wound healing assay, being 
this impaired proliferation a possible cause of the reduction of induced tumours.   
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The conditional knock-out model generated in this work will allow the study of the effects 
of the conditional genetic ablation of Aurora B at the cellular and organism level. Knock down of 
Aurora B using RNA interference of partial inactivation using chemical inhibitors results in 
abnormal cell divisions due to defects in chromosome segregation, spindle checkpoint and 
cytokinesis (Ditchfield et al., 2003; Hauf et al., 2003; Ruchaud et al., 2007). However, these studies 
have the caveat that the elimination of this protein is never complete and residual kinase activity 
may support certain activities. In our system, complete ablation of Aurora B in primary MEFs has 
revealed not only the previously described roles for Aurora B but also, additional and novel critical 
role for this kinase in other cell cycle processes such as spindle dynamics and G1/S progression. 
The importance of these results will be discussed later in this section.  
To understand the consequences of Aurora B ablation at the organism level, we are 
currently crossing the conditional mice with a knock-in strain that expresses the inducible Cre-
ERT2 recombinase to deplete Aurora B in mice in a time-controlled manner. This system will 
allow us to analyze Aurora B requirement for embryo mid-gestation, adult life or even more 
important for tumour progression. For this last purpose we are setting up crosses with an inducible 
knock-in model in which KRasV12 oncogenic form leads to clinically relevant pancreatic and lung 
tumours (Guerra et al., 2003). These in vivo experiments will therefore, be crucial to validate 
Aurora B as a therapeutical cancer target. 
  The tetracycline inducible model is a very interesting tool that will permit us to upregulate 
or to inactivate Aurora B expression by the action of transcriptional activators (tTA or rtTA) which 
can be modulated by the addition of tetracycline. The key innovation of this promoter-hijack 
approach is that in the modified allele, Aurora B coding region remains intact with introns and the 
3‟UTR of the gene while its promoter is replaced with a minimal promoter responsive to 
transcriptional activators. So far, we have generated mice with the following genotype: 
Aurkb(+/tet) , Rosa26(+/rtTA), in which, after addition of tetracycline (or the derivative 
doxicycline) to the drinking water of the animals, Aurora B will be overexpressed in an ubiquitous 
manner in the mice. This approach is extremely useful as it will help us to know whether the 
upregulation of Aurora B observed in tumours is indeed causally related to tumourigenesis or a 
reflection of the high proliferative index of cancerous cells. Similar approaches have been used to 
upregulate mitotic genes such as the Aurora B substrate Hec1/Ndc80 and the mitotic checkpoint 
component Mad2 in the mice (Diaz-Rodriguez et al., 2008; Sotillo et al., 2007). Increased 
expression of Hec1 drives aneuploidy and an elevation on spontaneous lung and liver tumors in 
mice; whereas, conditional overexpression of Mad2 predisposes animals to a wide range of early 
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onset, lethal tumours. These results suggest that upregulation of mitotic regulators also leads to 
aneuploidy increasing the risk of neoplastic transformation.   
3. Aurora B and Aurora C during early embryonic cell divisions  
Whereas a single Aurora kinase (increase-in-ploidy 1; Ipl1) exists in yeasts, two Aurora-like genes 
(A and B) are found in nematodes, insects and cold-blood vertebrates. Mammalian Aurora B and 
Aurora C are two closely related paralogs that probably evolved from a duplication event involving 
the ancestral Aurora B found in cold-blood vertebrates (Brown et al., 2004). Aurora B is widely 
expressed in dividing cells. Aurora C, however, displays a very restricted expression pattern with a 
clear abundance during spermatogenesis and oocyte fertilization (Figure 38). Aurora C deficiency 
results in viable mice with subfertility defects such as heterogeneous chromatin condensation, loose 
acrosomes and blunted sperm heads (Kimmins et al., 2007). Interestingly, Aurora C displays 
frameshift mutations in infertile patients with abnormal spermatozoa characterized by large heads 
and increased chromosomal content (Dieterich et al., 2007), suggesting a critical role in 
mammalian spermatogenesis. Overexpression of wild-type Aurora C or loss-of-function mutants 
induces mitotic aberrations consistent with the hypothesis that this protein may act as a CPC 
component (Sasai et al., 2004; Slattery et al., 2008; Yan et al., 2005). Aurora C is highly expressed 
in oocytes and fertilized oocytes and its expression decreases during the first embryo divisions to 
reach a minimum expression during the blastocyst stage (Hamatani et al., 2004). However, its 
relevance in CPC function and mitosis in vivo has not been elucidated given the reduced 
endogenous expression levels in cultured cell lines.  
The fact that Aurora B-null embryos survive up to post-implantation stages is certainly 
surprising given the earlier lethality of Incenp, Survivin or Borealin-deficient embryos (Cutts et al., 
1999; Uren et al., 2000; Yamanaka et al., 2008) and the critical roles of the CPC in cell division. 
During pre-implantation, Incenp is properly located in the absence of Aurora B and the phenotypes 
expected from perturbed CPC function are not observed. However, these embryos are sensitive to 
Aurora B/C inhibitors such as ZM1 or to the concomitant interference with Aurora B and Aurora C 
expression using RNA interference approaches. In addition, we have observed that interference 
with Aurora C, but not Aurora B, expression at the 2-cell stage results in a significant number of 
abnormal mitosis and cell arrest. These data are in agreement with the fact that Aurora C 
expression is higher than that of Aurora B during these early stages (Figure 38a) and with the cell 
cycle arrest induced by long double-stranded RNAs against Aurora C in 2-cell mouse embryos 
(Lykke-Andersen et al., 2008). The fact that Aurora C-null embryos develop normally (Kimmins et 
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al., 2007) suggests that acute ablation of this protein may have stronger effects than germline 
deletion. Alternatively, Aurora B may compensate for Aurora C downregulation, at least partially. 
All together, these results suggest that Aurora B and Aurora C can compensate each other and that 
Aurora C is probably the major CPC kinase during these early cell divisions in vivo. 
Despite the compensation by Aurora C in the early stages of embryonic development, 
Aurora B-null embryos die after implantation showing a dramatic increase in PM figures that 
finally lead to tetraploid or apoptotic figures both in vitro and in vivo. Incenp is not properly 
located in these cells suggesting a general defect in CPC function in these embryos. The massive 
arrest in PM in Aurora B-null embryos and the proper localization of Mad2 at the kinetochores 
suggests a robust, although transient, SAC in these developmental stages even in the absence of 
these CPC components. This contrast with the rapid exit from mitosis in primary Aurora B-null 
MEFs accompanied by lack of Mad2 at unattached kinetochores and degradation of cyclin B1 in 
these cells, and suggests differences in the strength of the SAC between these cell types. 
Similar conclusions have been obtained using mouse models deficient in the other CPC 
components. Incenp-deficient embryos reveal a high mitotic index, absence of post-metaphase 
stages and formation of micronuclei and irregular macronuclei with large chromosome 
complements (Cutts et al., 1999). Similarly, Survivin- or Borealin-deficient embryos became 
polyploid, exhibit increased apoptosis and failed to survive beyond 4.5 days post coitum (Uren et 
al., 2000; Yamanaka et al., 2008).  
4. Aurora B is a regulator of spindle dynamics and spindle pole integrity 
Aurora B-depleted MEFs display a significant increase in the number of multipolar spindles. The 
formation of multipolar spindles has also been observed in cells in which Incenp (Cutts et al., 
1999), Survivin (Yang et al., 2004) or Borealin (Gassmann et al., 2004) have been depleted by 
RNA interference or mouse knockouts.  
In addition to the multipolar spindles, Aurkb(/) mitotic cells display a significant 
overgrowild-typeh of astral microtubules and fragmentation of -tubulin MTOCs („multiaster‟ 
phenotype; Figure 47). Although a critical role for Aurora B in microtubule dynamics and the 
function of MTOCs has not previously demonstrated in mammals, there are some evidences from 
other CPC proteins or from depletion assays in Xenopus. Forced expression of Survivin influences 
microtubule dynamics reducing the pole-to-pole distance at metaphase and reduces microtubule 
nucleation from the centrosomes (Giodini et al., 2002; Rosa et al., 2006). On the other hand, 
suppression of Survivin by RNAi increased the number of microtubules nucleated by centrosomes 
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(Rosa et al., 2006). Whether the function of Survivin in microtubule dynamics is linked to its role 
as a CPC component remains controversial (Altieri, 2006; Lens et al., 2006). In fact, knock down 
or chemical inhibition of Aurora B in the same assays did not reveal any defect (Rosa et al., 2006), 
although this may be a consequence of residual Aurora B kinase activity. In the case of  Borealin, 
the supernumerary poles observed in multipolar figures are proposed to be formed by abnormal 
partitioning of chromosomes during anaphase (Gassmann et al., 2004). On the other hand, 
inhibition of Aurora B by antibody injection in Xenopus cells also led to the overgrowild-typeh of 
astral microtubules (Kallio et al., 2002) although the effects on pole fragmentation were not 
reported. All together, these data suggest a model (Figure 50) in that Aurora B may modulate 
microtubule dynamics in the spindle poles by inhibiting the formation of excessive poles/MTOCs 
and its microtubule nucleation activity therefore resulting in bipolar spindles. This inhibitory 
function may be in agreement with the requirement for the yeast Aurora kinase in spindle 
disassembly following the completion of anaphase (Buvelot et al., 2003). Whether the role of 
Aurora B in preventing spindle pole fractionation and astral microtubule overgrowild-typeh is 
linked to its ability to regulate proper microtubule-kinetochore attachment is not known.  
 
Figure 50. Roles of Aurora B in bipolar spindle assembly. Aurora B is essential for proper bipolar attachment between 
microtubules and kinetochores and its inhibition results in misaligned chromosomes. In addition, Aurora B is essential to 
prevent multiple MTOCs and growild-typeh of astral microtubules that are likely to result in multipolar (and in some cases 
monopolar by aggregation of MTOCs) spindles. Aurora B-null cells exit mitosis from these abnormal prometaphases 
resulting in nuclear fragmentation in the daughter cells. 
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5. Aurora B role in G1-S transition 
Aurora B seems to have a relevant function in G1/S transition as revealed by acute elimination of 
this protein in G0 cells. Aurkb(/) cells display a significant delay (>6 h in MEFs and >1 day in 
liver cells) in the entry into S-phase after serum stimulation of quiescent cells. As a comparison, the 
defect in S-phase entry is significantly stronger than that observed in primary MEFs deficient in 
Cdk4, Cdk6 or both Cdk4/6 (Malumbres et al., 2004), two major kinases regulating G1/S transition 
in mammals. Similarly, S-phase entry in Aurkb(+/–) mice after partial hepatectomy is dramatically 
impaired whereas double Cdk4;Cdk2-null mice display a normal regeneration of the liver in vivo 
(Barriere et al., 2007). How Aurora B regulates S-phase entry is not clear. Aurora B and Survivin 
are known to participate in mTOR signalling in T lymphocytes by promoting the phosphorylation 
of mTOR targets such as p70S6K (Song et al., 2007). On the other hand, Survivin has been 
reported to bind directly to Cdk4 and to trigger phosphorylation of the retinoblastoma protein (pRb) 
(Suzuki et al., 2000). A recent analysis of the endoreduplication checkpoint suggests that Aurora B 
is able to directly phosphorylate pRb at Ser780 (Nair et al., 2009), a residue also phosphorylated by 
Cdk4. It is also known that deletion of Survivin provokes G1 arrest accompanied by induction of 
p53 function although these defects are not rescued by concomitant ablation of p53 (Okada et al., 
2004; Yang et al., 2004). Our preliminary characterization of these pathways in Aurora B-deficient 
cells suggests a defect in p70S6K phosphorylation accompanied by induction of p21
Cip1
, a p53 
target involved in cell cycle arrest. Since genetic ablation of Aurora B is induced in quiescent/G0 
cells, these defects are not a consequence of mitotic aberrations but a specific requirement for 
Aurora B during entry into the cell cycle from quiescence. Further work will be required for a 
detailed characterization of the role of Aurora B or Aurora B-Survivin complexes in G1 and 
possible interactions with the G1/S machinery.  
6. Concluding remarks 
Aurora kinases have recently received much attention due to their possible involvement in tumor 
development and their therapeutic value (Keen and Taylor, 2004; Perez de Castro et al., 2008). All 
three Aurora kinases are overexpressed in different types of cancers (Giet et al., 2005; Keen and 
Taylor, 2004). Whereas initial efforts were focused to Aurora A, recent data suggest that Aurora B 
is a relevant cancer target (Girdler et al., 2006; Girdler et al., 2008). Thus, the critical roles of this 
kinase in the regulation of G1/S during interphase or spindle organization and chromosome 
congression during mitosis may have relevant implications for cancer therapy. In addition, the 
ability of Aurora C to drive CPC function suggests the relevance of this protein in specific cell 
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types. Intriguingly, whereas no point mutations have been reported for Aurora B, four missense 
changes in Aurora C (G18E, G53A, E114Q and H210Q) have been found in lung adenocarcinomas 
(Davies et al., 2005; Forbes et al., 2008). Some of these changes affect the T-loop or activation 
segment of the kinase domain, a conserved and key functional region known to harbor activating 
somatic mutations in other kinases in cancer (Davies et al., 2005). Understanding the specific 
requirements for Aurora B/C in vivo in different tissues may therefore provide useful information 
in future therapeutic efforts. 
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Conclusions 
 
1. Localization and kinase activity of Aurora B may be modulated by SUMO modification at 
a consensus site conserved in Aurora family members through evolution. This 
SUMOylation seems to favour proper localization of Aurora B at the centromeres during 
prometaphase and metaphase. 
 
2. Partial genetic ablation of Aurora B does not result in major alterations during mouse 
development but slightly favors tumor progression in aged mice. 
 
3. Aurora B is essential for mouse embryo development but dispensable during the early cell 
divisions due to the critical role of Aurora C during these first embryonic cycles. 
 
4. Aurora B deficiency is lethal after embryo implantation due to mitotic defects and 
activation of p53-dependent apoptotic pathways in embryonic cells and degeneration of 
trophoblast giant cells. 
 
5. Lack of Aurora B in advanced blastocysts arrests embryonic cells in prometaphase with 
misaligned chromosomes and spindle abnormalities, in the presence of a functional spindle 
assembly checkpoint.  
 
6. Aurora B is essential to maintain the stability of the bipolar spindle in MEFs by promoting 
proper bipolar attachments between microtubules and kinetochores and by keeping the 
integrity of spindle poles and asters.  
 
7. Aurora B regulates G1-S transition in vivo after partial hepatectomy and in primary MEFs, 
probably by modulating the mTOR pathway and/or the levels of the p53 effector p21
Cip1
 . 
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Conclusiones 
 
1. La localización y actividad de Aurora B está regulada por la modificación por SUMO en 
un sitio consenso de la proteína conservado durante la evolución en los miembros de la 
familia de Aurora. Esta SUMOilación  parece favorecer la correcta localización de Aurora 
B en el centrómero durante prometafase y metafase. 
 
2. La eliminación genética parcial de Aurora B no da lugar a grandes problemas durante el 
desarrollo de la vida del ratón; pero sí incrementa la susceptibilidad a desarrollar tumores 
espontáneos en ratones de avanzada edad. 
 
3. Aurora B es esencial durante el desarrollo embrionario del ratón, pero resulta dispensable 
durante las primeras divisiones celulares debido al efecto compensatorio que ejerce Aurora 
C en estos primeros ciclos embrionarios.   
 
4. La deficiencia embrionaria de Aurora B es letal poco tiempo después de la implantación 
del embrión debido a defectos mitóticos y a la activación de rutas apoptóticas dependientes 
de p53 en las células embrionarias, y a la degeneración de las células gigantes del 
trofoblasto. 
 
5. La ausencia de Aurora B en blastocistos avanzados produce un arresto celular en 
prometafase con cromosomas no alineados y abnormalidades en el huso mitótico, todo ello 
en presencia de un punto de control mitótico funcional.  
 
6. Aurora B mantiene la estabilidad del huso mitótico bipolar en MEFs a través de promover 
el correcto anclaje entre los microtúbulos del huso y los cinétocoros, y de guardar la 
integridad de los polos y de los ásteres del huso. 
 
7. Aurora B regula la transición G1/S en el hígado del ratón, después de realizar una 
hepatectomía parcial, y en fibroblastos en cultivo; seguramente  mediante la regulación de 
la ruta de mTOR y/o de los niveles de p21
Cip
, un conocido efector de p53. 
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